<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="pmc-domain-id">2745</journal-id><journal-id journal-id-type="pmc-domain">jclinmed</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12429768</article-id><article-id pub-id-type="pmcid-ver">PMC12429768.1</article-id><article-id pub-id-type="pmcaid">12429768</article-id><article-id pub-id-type="pmcaiid">12429768</article-id><article-id pub-id-type="doi">10.3390/jcm14176045</article-id><article-id pub-id-type="publisher-id">jcm-14-06045</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Nationwide Trends and Outcomes of Alcohol Use Disorders in COPD Hospitalizations in Spain, 2016&#8211;2023</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>G&#243;mez-Garcia</surname><given-names initials="T">Teresa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af1-jcm-14-06045" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5906-9393</contrib-id><name name-style="western"><surname>Jim&#233;nez-Garcia</surname><given-names initials="R">Rodrigo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-jcm-14-06045" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5790-1959</contrib-id><name name-style="western"><surname>Hern&#225;ndez-Barrera</surname><given-names initials="V">Valent&#237;n</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af3-jcm-14-06045" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5551-5181</contrib-id><name name-style="western"><surname>L&#243;pez-de-Andr&#233;s</surname><given-names initials="A">Ana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af4-jcm-14-06045" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9897-4847</contrib-id><name name-style="western"><surname>Carabantes-Alarcon</surname><given-names initials="D">David</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af2-jcm-14-06045" ref-type="aff">2</xref><xref rid="c1-jcm-14-06045" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jim&#233;nez-Sierra</surname><given-names initials="A">Ana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af5-jcm-14-06045" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6604-5197</contrib-id><name name-style="western"><surname>Labajo-Gonz&#225;lez</surname><given-names initials="E">Elena</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af6-jcm-14-06045" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bodas-Pinedo</surname><given-names initials="A">Andr&#233;s</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af2-jcm-14-06045" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>de-Miguel-Diez</surname><given-names initials="J">Javier</given-names></name><xref rid="af1-jcm-14-06045" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Leuppi</surname><given-names initials="JD">J&#246;rg Daniel</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jcm-14-06045"><label>1</label>Respiratory Care Department, Hospital General Universitario Gregorio Mara&#241;&#243;n, Instituto de Investigaci&#243;n Sanitaria Gregorio Mara&#241;&#243;n (IiSGM), Universidad Complutense de Madrid, 28007 Madrid, Spain; <email>t.gomez@salud.madrid.org</email> (T.G.-G.); <email>javier.miguel@salud.madrid.org</email> (J.d.-M.-D.)</aff><aff id="af2-jcm-14-06045"><label>2</label>Department of Public Health and Maternal &amp; Child Health, Faculty of Medicine, Universidad Complutense de Madrid, IdISSC, 28040 Madrid, Spain; <email>rodrijim@ucm.es</email> (R.J.-G.); <email>abodas@ucm.es</email> (A.B.-P.)</aff><aff id="af3-jcm-14-06045"><label>3</label>Preventive Medicine and Public Health Teaching and Research Unit, Health Sciences Faculty, Universidad Rey Juan Carlos, 28922 Madrid, Spain; <email>valentin.hernandez@urjc.es</email></aff><aff id="af4-jcm-14-06045"><label>4</label>Department of Public Health and Maternal &amp; Child Health, Faculty of Pharmacy, Universidad Complutense de Madrid, IdISSC, 28040 Madrid, Spain; <email>anailo04@ucm.es</email></aff><aff id="af5-jcm-14-06045"><label>5</label>Faculty of Medicine, Universidad San Pablo Ceu, 28668 Madrid, Spain; <email>a.jimenez100@usp.ceu.es</email></aff><aff id="af6-jcm-14-06045"><label>6</label>Department of Legal Medicine, Psychiatry and Pathology, Faculty of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain; <email>melabajo@ucm.es</email></aff><author-notes><corresp id="c1-jcm-14-06045"><label>*</label>Correspondence: <email>dcaraban@ucm.es</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>14</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">496787</issue-id><elocation-id>6045</elocation-id><history><date date-type="received"><day>08</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>01</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jcm-14-06045.pdf"/><abstract><p><bold>Background:</bold> Chronic obstructive pulmonary disease (COPD) is a prevalent condition with high morbidity and mortality, often accompanied by comorbidities such as alcohol use disorder (AUD). A thorough understanding of the interaction between COPD and AUD is crucial for improving patient outcomes and addressing management challenges. <bold>Objectives:</bold> This study analyzed temporal trends, clinical characteristics, and hospital outcomes associated with AUD among adults hospitalized with COPD in Spain between 2016 and 2023. <bold>Methods:</bold> A population-based cohort study was conducted using the Spanish Hospital Discharge Registry. We included adults aged &#8805;40 years with a diagnosis of COPD. AUD was identified through ICD-10 codes. Temporal trends in AUD prevalence were evaluated using Joinpoint regression, stratified by sex. We also assessed clinical characteristics including pneumonia, obesity, asthma, obstructive sleep apnea (OSA), supplemental oxygen use, long-term steroid use, and mechanical ventilation. Outcomes analyzed included ICU admission and in-hospital mortality (IHM). <bold>Results:</bold> Among 2,545,151 COPD hospitalizations, 263,568 (10.35%) had an AUD diagnosis. AUD prevalence rose from 8.66% in 2016 to 12.57% in 2023, with a sharper increase in women. Patients with AUD were younger and had higher rates of tobacco use (84.11% vs. 49.33%; <italic toggle="yes">p</italic> &lt; 0.001) and psychiatric disorders. Multivariable analysis showed male sex, substance use, psychiatric illness, and external cause admissions were independently associated with AUD. Although overall IHM was lower in AUD patients (7.46% vs. 8.2%; <italic toggle="yes">p</italic> &lt; 0.001), it increased with age, pneumonia, COVID-19, and higher comorbidity. IHM rose progressively, peaking in 2023 (15.6%). <bold>Conclusions:</bold> AUD prevalence in COPD hospitalizations increased significantly, especially in women. IHM also rose over time. These results highlight the need for integrated approaches targeting mental health and substance use in COPD management.</p></abstract><kwd-group><kwd>chronic obstructive pulmonary disease</kwd><kwd>COPD</kwd><kwd>alcohol use disorder</kwd><kwd>psychiatric comorbidities prevalence</kwd><kwd>substance use hospitalization</kwd><kwd>mortality</kwd><kwd>sex</kwd></kwd-group><funding-group><award-group><funding-source>Sociedad Madrile&#241;a de Neumolog&#237;a y Cirug&#237;a de T&#243;rax (NEUMOMADRID)</funding-source><award-id>XXII Awards Edition (2022)</award-id></award-group><award-group><funding-source>Sociedad Espa&#241;ola de Neumolog&#237;a y Cirug&#237;a de T&#243;rax (SEPAR)</funding-source><award-id>1309</award-id></award-group><award-group><funding-source>the Madrid Government (Comunidad de Madrid-Spain)</funding-source></award-group><award-group><funding-source>Universidad Complutense de Madrid, Grupo de Investigaci&#243;n en Epidemiolog&#237;a de las Enfermedades Cr&#243;nicas de Alta Prevalencia en Espa&#241;a</funding-source><award-id>970970</award-id></award-group><funding-statement>This study is part of the research funded by the Sociedad Madrile&#241;a de Neumolog&#237;a y Cirug&#237;a de T&#243;rax (NEUMOMADRID), XXII Awards Edition (2022), and the Sociedad Espa&#241;ola de Neumolog&#237;a y Cirug&#237;a de T&#243;rax (SEPAR), Research Aid 2022, project number 1309. This work has also been supported by the Madrid Government (Comunidad de Madrid-Spain) under the Multiannual Agreement with Universidad Complutense de Madrid in the line Excellence Programme for university teaching staff, in the context of the V PRICIT (Regional Programme of Research and Technological Innovation), and by Universidad Complutense de Madrid, Grupo de Investigaci&#243;n en Epidemiolog&#237;a de las Enfermedades Cr&#243;nicas de Alta Prevalencia en Espa&#241;a (970970).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-jcm-14-06045"><title>1. Introduction</title><p>Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition characterized by persistent airflow limitation and an enhanced chronic inflammatory response in the airways and lungs, primarily due to exposure to noxious particles or gases such as tobacco smoke [<xref rid="B1-jcm-14-06045" ref-type="bibr">1</xref>]. It is a widespread and debilitating illness, affecting approximately 11.8% of the Spanish population aged 40 and older, according to the EPISCAN II [<xref rid="B2-jcm-14-06045" ref-type="bibr">2</xref>] study, conducted in 2017, and is associated with significant morbidity and mortality. Notably, over 80% of COPD patients are estimated to have at least one comorbid chronic condition. The most prevalent comorbidities include cardiovascular diseases, diabetes mellitus, osteoporosis, musculoskeletal disorders, and mental health conditions such as anxiety and depression [<xref rid="B3-jcm-14-06045" ref-type="bibr">3</xref>]. Multimorbidity in COPD not only increases hospital admissions in terms of frequency and duration [<xref rid="B4-jcm-14-06045" ref-type="bibr">4</xref>] but also drives extensive direct medical costs such as emergency visits, medications, and long-term oxygen therapy, as well as significant indirect costs, including reduced work productivity, premature retirement, impaired quality of life, and substantial caregiver burden [<xref rid="B5-jcm-14-06045" ref-type="bibr">5</xref>].</p><p>Within this context, patients hospitalized with COPD frequently present with concurrent mental and behavioral disorders due to substance abuse (MBDA) [<xref rid="B6-jcm-14-06045" ref-type="bibr">6</xref>,<xref rid="B7-jcm-14-06045" ref-type="bibr">7</xref>]. MBDA describes a spectrum of psychiatric conditions directly caused by the harmful or dependent use of psychoactive substances. This includes both substance use disorders (persistent and problematic patterns of misuse leading to clinical impairment) and substance-induced disorders, which manifest as psychiatric symptoms during periods of intoxication or withdrawal [<xref rid="B8-jcm-14-06045" ref-type="bibr">8</xref>]. Alcohol Use Disorder (AUD) is a prevalent condition in the general population, affecting approximately 13.9% of U.S. adults annually, according to DSM-5 criteria in the NESARC-III study [<xref rid="B9-jcm-14-06045" ref-type="bibr">9</xref>]. The prevalence of AUD among COPD patients varies across studies, influenced by multiple factors including study design, population demographics, and diagnostic criteria [<xref rid="B10-jcm-14-06045" ref-type="bibr">10</xref>,<xref rid="B11-jcm-14-06045" ref-type="bibr">11</xref>]. While some studies report lower prevalence rates, others indicate higher rates, particularly among specific subgroups such as older males with psychological distress. AUD in COPD patients is characterized by distinct demographic profiles and socioeconomic vulnerabilities [<xref rid="B6-jcm-14-06045" ref-type="bibr">6</xref>]. Its presence leads to more severe inpatient complications, elevated costs, and greater likelihood of readmission, often worsening outcomes when combined with other comorbidities [<xref rid="B6-jcm-14-06045" ref-type="bibr">6</xref>].</p><p>AUD may influence the development and progression of Chronic Obstructive Pulmonary Disease (COPD) through both biological and behavioral mechanisms. Biologically, chronic alcohol consumption impairs lung immunity by suppressing alveolar macrophage function, increasing oxidative stress, and disrupting the integrity of the pulmonary epithelial barrier [<xref rid="B12-jcm-14-06045" ref-type="bibr">12</xref>]. These effects collectively heighten susceptibility to respiratory infections and may accelerate COPD progression. Indirectly, AUD is strongly associated with other substance use disorders, most notably tobacco dependence, which remains the leading etiological factor for COPD. In addition, elevated rates of illicit drug use (e.g., cocaine, cannabinoids, opioids) among individuals with AUD further compromise respiratory health and may contribute to airway inflammation or acute exacerbations.</p><p>Chronic and heavy alcohol consumption adversely affects COPD by compromising multiple pulmonary defense mechanisms. Long-term ethanol exposure impairs mucociliary clearance by disrupting ciliary beating and CFTR-mediated airway hydration, thereby increasing susceptibility to pathogen colonization and infection [<xref rid="B13-jcm-14-06045" ref-type="bibr">13</xref>]. Concurrently, alcohol induces significant oxidative stress and depletes alveolar glutathione&#8212;key antioxidant protection in the lung&#8212;leading to diminished alveolar macrophage function and weakened epithelial barrier integrity, which further impairs pulmonary host defense and potentiates airway injury and COPD progression [<xref rid="B14-jcm-14-06045" ref-type="bibr">14</xref>]. Overall, chronic heavy drinking appears to exacerbate COPD symptoms by increasing the frequency of respiratory infections, accelerating decline in lung function, and elevating the risk of exacerbations and mortality.</p><p>Understanding the multifaceted nature of COPD and its associated conditions is crucial for improving patient outcomes and optimizing healthcare resource allocation. The intersection of COPD with AUD introduces unique challenges in patient management, affecting clinical presentation, treatment adherence, and overall prognosis. This study aims to analyze retrospectively temporal trends, clinical characteristics, and hospital outcomes associated with AUD among adults hospitalized with COPD in Spain between 2016 and 2023.</p></sec><sec id="sec2-jcm-14-06045"><title>2. Materials and Methods</title><p>We conducted a population-based observational descriptive study using data from the Spanish National Hospital Discharge Database (SNHDD), managed by the Spanish Ministry of Health. The SNHDD is a mandatory administrative registry that compiles information on all hospital discharges from public and private hospitals in Spain. It includes only inpatient admissions and excludes data from patients treated exclusively in emergency departments.</p><p>The database contains detailed information on patient demographics (age, sex), admission and discharge dates, discharge destination (recovery, transfer, or in-hospital death), primary and up to 19 secondary diagnoses, up to 20 diagnostic or therapeutic procedures, and admission to intensive care units (ICU). Diagnoses and procedures are coded using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) [<xref rid="B15-jcm-14-06045" ref-type="bibr">15</xref>].</p><p>The study period ranged from 1 January 2016, to 31 December 2023, and included all hospital discharges from public hospitals in Spain. The study population consisted of individuals aged &#8805;40 years with a diagnosis of COPD, identified by the presence of ICD-10 code J40 to J44 and J47 in any of the 20 diagnostic fields. We excluded those with missing data on sex, admission or discharge dates, or discharge status.</p><p>The inclusion criteria for this study were as follows: adults aged &#8805;40 years; patients with a diagnosis of chronic obstructive pulmonary disease (COPD), identified by the presence of ICD-10 codes J40&#8211;J44 and J47 in any of the 20 diagnostic fields; and all hospital discharges from public hospitals in Spain between 1 January 2016, and 31 December 2023. Only inpatient admissions were considered.</p><p>The exclusion criteria were: missing data on sex, admission or discharge dates, or discharge status; and patients treated exclusively in emergency departments, as SNHDD only collects information on inpatient hospitalizations.</p><p>The primary outcome was the presence of AUD, defined by the ICD-10 code F10 in any diagnostic position. The analysis was stratified by sex. Covariates included year of admission, age (as a continuous variable and in categorized age groups), and hospitalization characteristics such as ICU admission and in-hospital mortality (IHM).</p><p>To assess comorbidity, we applied the Charlson Comorbidity Index, which includes the following conditions: acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular disease, dementia, pulmonary disease, connective tissue disease, peptic ulcer disease, liver disease, diabetes, diabetes with complications, hemiplegia or paraplegia, renal disease, cancer, metastatic cancer, severe liver disease, HIV disease [<xref rid="B16-jcm-14-06045" ref-type="bibr">16</xref>]. Specific clinical conditions of interest included obesity, depression, anxiety disorders, specific personality disorders, and external causes of morbidity and mortality. We also analyzed the presence of pneumonia, obesity, asthma, obstructive sleeping apnea (OSA), the use of supplemental oxygen, long term use of steroids and mechanical ventilation during hospitalization. Additionally, other substance use disorders were evaluated, including tobacco, cocaine use, cannabis use, and opioid dependence. Since 2020, the presence of COVID-19 was also considered. Regarding the outcomes of hospital admission of the subjects included in the study, we analyzed the admission to ICU and IHM.</p><p>All ICD-10 codes used to define exposure and covariates are detailed in <xref rid="app1-jcm-14-06045" ref-type="app">Table S1</xref>.</p><sec id="sec2dot1-jcm-14-06045"><title>2.1. Statistical Analysis</title><p>The study population was described by year and stratified by sex. Quantitative variables were summarized using means and standard deviations when normally distributed (normality assessed using the Kolmogorov&#8211;Smirnov test) and as medians and interquartile ranges (IQR) when non-normally distributed. Categorical variables were presented as frequencies and percentages.</p><p>Temporal trends in the prevalence of AUD among hospitalizations COPD were assessed separately for men and women using Joinpoint regression analysis. This method allows for the identification of statistically significant changes in trend patterns and estimates the annual percent change (APC) over time [<xref rid="B17-jcm-14-06045" ref-type="bibr">17</xref>].</p><p>For other covariates, temporal trends were evaluated using linear regression for continuous variables, the Jonckheere&#8211;Terpstra test for non-normally distributed variables, and the Cochran&#8211;Mantel&#8211;Haenszel test for categorical variables.</p><p>In the bivariable analysis, comparisons between groups were made using Student&#8217;s <italic toggle="yes">t</italic>-test for normally distributed continuous variables, the Mann&#8211;Whitney U test for non-normally distributed variables, and Fisher&#8217;s exact test for categorical variables. Where applicable, <italic toggle="yes">p</italic>-values were adjusted for multiple comparisons using the Bonferroni&#8211;Holm correction method.</p><p>To identify independent factors associated with AUD among patients with COPD, we performed unconditional multivariable logistic regression using a generalized logit function, stratified by sex. The same multivariable approach was used to evaluate factors independently associated with in-hospital mortality among patients with both COPD and AUD. Only variables showing a statistically significant association in the bivariable analysis were considered in the multivariable models. Model development followed the strategy described by Hosmer and colleagues [<xref rid="B18-jcm-14-06045" ref-type="bibr">18</xref>]. Results were expressed as adjusted odds ratios (aORs) with 95% confidence intervals (CIs).</p><p>All statistical analyses were conducted using Stata software, version 14 (StataCorp, College Station, TX, USA). A two-tailed <italic toggle="yes">p</italic>-value &lt; 0.05 was considered statistically significant.</p></sec><sec id="sec2dot2-jcm-14-06045"><title>2.2. Ethical Considerations</title><p>This study was conducted using data from the SNHDD, an administrative dataset owned and maintained by the Spanish Ministry of Health. Access to the SNHDD requires submission of a formal request specifying the research objectives and methodology. The Ministry evaluates each request from both a scientific and ethical standpoint before authorizing the release of the data.</p><p>The dataset provided for this study was completely anonymized and did not contain any personally identifiable information. As the data were obtained for research purposes in an anonymous and aggregate format, and in accordance with Spanish legislation governing the secondary use of health data, ethical approval from a clinical research ethics committee was not required.</p><p>Moreover, the database was made available to the research team free of charge, and its use complied fully with national regulations on the protection of personal data and the ethical standards of epidemiological research.</p><p>The Spanish legislation is available at: Ley 14/2007; de 3 de julio, de investigaci&#243;n biom&#233;dica [<xref rid="B19-jcm-14-06045" ref-type="bibr">19</xref>]. Also, according to this law, as this is an administrative database, informed consent is not necessary.</p></sec></sec><sec sec-type="results" id="sec3-jcm-14-06045"><title>3. Results</title><p>Between 2016 and 2023, a total of 2,545,151 hospitalizations involving patients with COPD were recorded in Spain, of which 263,568 (10.35%) included a co-diagnosis of AUD. Joinpoint regression analysis revealed a statistically significant increase in AUD prevalence among hospitalized COPD patients between 2016 and 2021, rising from 8.66% to 12.26%. Although the upward trend appeared to continue through 2023, the increase was no longer statistically significant after 2021 (<xref rid="jcm-14-06045-f001" ref-type="fig">Figure 1</xref>, <xref rid="jcm-14-06045-f002" ref-type="fig">Figure 2</xref> and <xref rid="jcm-14-06045-f003" ref-type="fig">Figure 3</xref>).</p><p>Stratified by sex, this trend was more pronounced in men, whose AUD prevalence rose from 10.28% in 2016 to 15.29% in 2021 (APC: 7.11%, <italic toggle="yes">p</italic> &lt; 0.05), with no significant change thereafter. Among women, despite a lower baseline prevalence, AUD still increased significantly from 2.97% to 5.03% over the full study period (APC: 7.87%, <italic toggle="yes">p</italic> &lt; 0.05) (<xref rid="jcm-14-06045-f003" ref-type="fig">Figure 3</xref>). In 2016, men accounted for 92.41% of AUD cases among COPD hospitalizations; this proportion gradually declined to 89.05% by 2023, reflecting an increasing representation of women&#8212;from 7.59% in 2016 to 10.95% in 2023 (<xref rid="jcm-14-06045-t001" ref-type="table">Table 1</xref>). This shift indicates a significant rise in female AUD cases (<italic toggle="yes">p</italic> &lt; 0.001). Meanwhile, the mean age of COPD patients with AUD increased significantly during the study period, rising from 67.68 to 69.18 years (<italic toggle="yes">p</italic> &lt; 0.001), with particularly notable growth observed in the 50&#8211;65 and 65&#8211;80 year age brackets.</p><p>The clinical characteristics and hospital outcomes of COPD patients with AUD&#8212;summarized in <xref rid="jcm-14-06045-t001" ref-type="table">Table 1</xref>&#8212;reveal a notable rise in substance use from 2016 to 2023. Cocaine use experienced the most pronounced increase, doubling from 2.49% to 4.86%. In the same period, cannabis use climbed from 2.03% to 3.47%, opioid dependence grew from 2.40% to 3.27%, and tobacco consumption increased modestly from 82.5% to 84.73% (<italic toggle="yes">p</italic> &lt; 0.001 for all). Most comorbidities also trended upward&#8212;pneumonia, sleep apnea, obesity, anxiety, personality disorders, and admissions for external causes all showed statistically significant increases (<italic toggle="yes">p</italic> &lt; 0.001)&#8212;whereas the prevalence of depression remained unchanged (<italic toggle="yes">p</italic> = 0.465). The Charlson Comorbidity Index rose modestly from 1.10 to 1.16 (<italic toggle="yes">p</italic> &lt; 0.001). COVID 19 prevalence increased from 2.83% in 2020 to 9.48% in 2022, ICU admissions rose slightly (7.12% &#8594; 7.79%), and IHM peaked in 2020 (8.48%) then decreased to 7.34%, with an overall significant upward trend (<italic toggle="yes">p</italic> &lt; 0.001) (<xref rid="jcm-14-06045-t001" ref-type="table">Table 1</xref>).</p><p>Comparing COPD patients with versus without AUD (<xref rid="jcm-14-06045-t002" ref-type="table">Table 2</xref>), those with AUD were significantly younger (68.44 vs. 75.44 years; <italic toggle="yes">p</italic> &lt; 0.001) and had higher prevalences of substance use&#8212;cocaine (3.69% vs. 0.45%), cannabinoids (2.79% vs. 0.34%), opioids (2.95% vs. 0.65%), and tobacco (84.11% vs. 49.33%) (all <italic toggle="yes">p</italic> &lt; 0.001)&#8212;along with more frequent psychiatric comorbidities (depression 4.44% vs. 4.15%; anxiety 4.02% vs. 3.57%; personality disorders 1.62% vs. 0.42%). Those with AUD had lower rates of pneumonia (10.42% vs. 11.23%) and asthma (2.67% vs. 4.73%), but higher prevalences of sleep apnea (13.19% vs. 12.66%) and obesity (14.52% vs. 12.78%). However, among women with AUD, sleep apnea (7.93% vs. 9.43%) and obesity (14.05% vs. 16.73%) were lower than in their non AUD counterparts (<italic toggle="yes">p</italic> &lt; 0.001). The overall Charlson comorbidity Index was slightly higher in AUD patients (1.15 vs. 1.13; <italic toggle="yes">p</italic> &lt; 0.001), though women with AUD had a lower index than women without (0.98 vs. 1.03; <italic toggle="yes">p</italic> &lt; 0.001). COVID 19 was less frequent among AUD patients (3.01% vs. 3.54%). ICU admission rates were higher (7.25% vs. 5.8%), especially in women (7.82% vs. 5.23%), while IHM was lower in the AUD group (7.46% vs. 8.20%) across sexes.</p><p>Regarding sex differences among AUD patients (<xref rid="app1-jcm-14-06045" ref-type="app">Table S2</xref>), men (<italic toggle="yes">n</italic> = 248,836) were older than women (<italic toggle="yes">n</italic> = 24,732; 68.93 vs. 63.45 years; <italic toggle="yes">p</italic> &lt; 0.001). Women showed higher prevalences of cocaine (5.92% vs. 3.47%), cannabinoids (4.39% vs. 2.63%), and opioids (5.26% vs. 2.73%) (<italic toggle="yes">p</italic> &lt; 0.001), whereas tobacco use was slightly higher among men (84.12% vs. 83.96%; <italic toggle="yes">p</italic> &lt; 0.001). Psychiatric conditions&#8212;depression (12.18% vs. 3.67%), anxiety (11.47% vs. 3.27%), and personality disorders (6.2% vs. 1.16%)&#8212;occurred more frequently in women (<italic toggle="yes">p</italic> &lt; 0.001), and external-cause admissions were also higher (7.74% vs. 5.24%; <italic toggle="yes">p</italic> &lt; 0.001). Men had higher Charlson Comorbidity Index scores (1.15 vs. 0.98; <italic toggle="yes">p</italic> &lt; 0.001), as well as greater prevalence of asthma, obesity, sleep apnea, pneumonia, and COVID 19 diagnoses, while ICU admission was more frequent in women (7.82% vs. 7.2%; <italic toggle="yes">p</italic> &lt; 0.001) and IHM was higher in men (7.63% vs. 5.76%). Female patients received more intensive interventions&#8212;corticosteroids, supplemental oxygen, invasive and non invasive ventilation (all <italic toggle="yes">p</italic> &lt; 0.001).</p><p>Multivariable logistic regression (<xref rid="jcm-14-06045-t003" ref-type="table">Table 3</xref>) identified several independent predictors of AUD. Using the 40&#8211;50 year age group as the reference, the aOR for the 50&#8211;65 year group was 1.09 in men and 0.95 in women. In the 65&#8211;80 year group, odds decreased to 0.60 for men and 0.54 for women, while those aged &#8805;80 showed further reductions (men: aOR 0.25; women: aOR 0.15). These findings indicate that the likelihood of AUD increases modestly in middle-aged men but declines progressively in older age groups across both sexes. Tobacco conferred the highest AUD risk (aOR 3.95 in men, 4.84 in women), followed by cocaine, cannabinoids, and opioids. Psychiatric disorders (personality disorders aOR 2.04/3.35; depression aOR 1.34; anxiety aOR 1.21), external causes (aOR 1.55), higher Charlson comorbidity Index (1.20/1.27), and obesity in men (aOR 1.11) were significant predictors. AUD odds increased annually, reaching aORs of 1.40 (men) and 1.32 (women) in 2023, with male sex strongly associated (aOR 3.54).</p><p>The cohort was stratified by IHM status (<xref rid="jcm-14-06045-t004" ref-type="table">Table 4</xref>), revealing that patients who died during admission were significantly older (mean age 71.74 vs. 68.17 years; <italic toggle="yes">p</italic> &lt; 0.001), with mortality rates rising sharply with age and reaching 23.82% in those aged &#8805;80 years. Non-survivors exhibited lower rates of substance use and comorbid conditions such as asthma, sleep apnea, and obesity (<italic toggle="yes">p</italic> &lt; 0.001). Conversely, they had higher prevalences of pneumonia, ICU admission (18.29% vs. 6.36%), COVID-19 infection (5.22% vs. 2.84%), and increased need for supplemental oxygen, invasive ventilation (11.59% vs. 1.71%), and non-invasive ventilation (8.44% vs. 4.01%). IHM escalated from 8.81% in 2016 to 15.6% in 2023, with the highest rate observed in women (17.96%).</p><p>Finally, predictors of IHM (<xref rid="jcm-14-06045-t005" ref-type="table">Table 5</xref>) showed that age was the strongest risk factor (with women &#8805; 80 years showing aOR 4.72), along with pneumonia (aOR 1.41), COVID 19 (aOR 1.80), and higher CCI (aOR 1.30). Protective associations were observed for obesity (aOR 0.66), sleep apnea (aOR 0.67), depression/anxiety (aOR 0.81), and personality disorders (aOR 0.76). Mortality risk was elevated during the COVID years of 2020 (aOR 1.23) and 2021 (aOR 1.14), without further increase afterward, and male sex modestly increased mortality risk (aOR 1.06).</p></sec><sec sec-type="discussion" id="sec4-jcm-14-06045"><title>4. Discussion</title><p>In our study, we found that between 2016 and 2023, 10.35% of patients hospitalized with COPD in Spain had a co-diagnosis of AUD. Moreover, the prevalence of AUD among COPD inpatients increased steadily over this period. These findings are consistent with data from U.S. inpatient cohorts. For instance, a nationwide review of COPD and asthma admissions (2012&#8211;2015) reported a documented AUD prevalence of 4.1%, with AUD associated with greater respiratory failure, increased need for mechanical ventilation, prolonged hospital stay, and higher 30-day readmission rates [<xref rid="B6-jcm-14-06045" ref-type="bibr">6</xref>]. Similarly, a U.S. emergency department study found that 2.11% of visits among COPD/asthma patients involved alcohol misuse; these individuals were older (mean age 58.1 vs. 53.7), predominantly male (69.5%), and faced elevated rates of respiratory failure and ventilation [<xref rid="B6-jcm-14-06045" ref-type="bibr">6</xref>]. More pertinent to our population, the 2022 EDADES survey revealed that 76.5% of adults aged 15&#8211;64 in Spain had consumed alcohol in the past year. Notably, 10.5% reported daily alcohol consumption, and 14.7% had experienced binge drinking in the past year [<xref rid="B20-jcm-14-06045" ref-type="bibr">20</xref>]. This underscores a high baseline prevalence of alcohol use in Spain. Regarding the impact of the COVID-19 pandemic, Oliv&#225;n-Bl&#225;zquez et al. reported a substantial worsening of alcohol use disorder during the first year of the pandemic in Spain, based on primary care electronic records [<xref rid="B21-jcm-14-06045" ref-type="bibr">21</xref>]. Although the study did not specifically evaluate respiratory diagnoses, the observed exacerbation in alcohol misuse during this period highlights a potential indirect relationship with chronic respiratory diseases such as chronic bronchitis and COPD. Despite these valuable epidemiological insights, to our knowledge, there is a lack of European or Spanish studies specifically assessing AUD among COPD patients in hospital or primary-care settings. This underscores the urgent need for further research to address this significant interaction between alcohol misuse and chronic respiratory diseases.</p><p>In our cohort, male patients continued to predominate; however, the rate of increase in prevalence over time was notably steeper among women, resulting in a narrowing of the gender gap. Although men represented the majority of cases, the proportion of women affected grew increasingly over the study period. Patients with AUD were, on average, several years younger than their non-AUD counterparts, and the likelihood of AUD decreased with advancing age, particularly in older age brackets relative to middle-aged adults. Regarding sex- and age-related dynamics, our data not only mirror U.S. patterns in male predominance and younger age of AUD patients but also reveal a pronounced demographic shift: the accelerated rise of AUD in female COPD patients, despite their low initial prevalence, highlights a trend that pre-existing literature has not fully addressed.</p><p>The accelerated rise of AUD among women and its higher prevalence in younger populations can be attributed to both sociocultural shifts and biological vulnerabilities. Over the past two decades, changing gender roles and greater social acceptability of female drinking have contributed to narrowing sex gaps in alcohol consumption. These sociocultural changes not only influence drinking behaviors but may also interact with inherent biological susceptibilities, further intensifying the risk in women. Women develop AUD more rapidly than men, a pattern known as &#8220;telescoping&#8221;, and experience greater physical harm at lower levels of alcohol intake. This is largely attributed to biological differences, including lower gastric alcohol dehydrogenase activity, less total body water, and higher body fat percentage, which lead to higher blood alcohol concentrations. As a result, women are more vulnerable to alcohol-related liver disease, cardiovascular complications, and neurocognitive damage. Psychosocial factors such as greater exposure to internalizing disorders and stress-related drinking further compound this risk [<xref rid="B22-jcm-14-06045" ref-type="bibr">22</xref>].</p><p>The observed decline in AUD probability with advancing age is consistent with general population trends showing lower substance use among older adults. For instance, a study utilizing data from the National Comorbidity Survey Replication found that the prevalence of 12-month substance use disorders was lower in older adults (65 years and older) compared to younger age groups, with 0% prevalence for any substance use disorder in the 65 and older group [<xref rid="B23-jcm-14-06045" ref-type="bibr">23</xref>]. The lower prevalence of AUD in older adults may be attributed to various factors, including age-related physiological changes that reduce alcohol tolerance, social role changes such as retirement and social isolation, and potential underdiagnosis due to overlapping symptoms with other age-related conditions [<xref rid="B24-jcm-14-06045" ref-type="bibr">24</xref>].</p><p>The high prevalence of tobacco consumption (84.02%) among patients with AUD in our cohort underscores the significant overlap between substance use disorders. Moreover, our analysis also indicates that substance use was markedly higher in the AUD group compared to those without AUD across all categories. Specifically, cocaine use was 3.69% in the AUD group versus 0.45% in the non-AUD group; cannabinoid use was 4.39% versus 1.88%; and opioid dependence was 5.26% versus 1.83%. These findings align with previous research indicating that individuals with AUD are more likely to engage in other substance use behaviors. For example, a study found that individuals in opioid antagonist treatment had a higher prevalence of substance misuse, including tobacco, alcohol, and illicit drugs, compared to those without substance misuse [<xref rid="B25-jcm-14-06045" ref-type="bibr">25</xref>].</p><p>The fact that patients diagnosed with AUD frequently exhibit higher prevalence of use of other substances, including cocaine, cannabis, opioids, and notably tobacco, can be largely understood through the lens of self-medication and syndrome overlap. The self-medication hypothesis posits that these individuals may turn to alcohol and other psychoactive substances in attempts to alleviate distressing mood or anxiety symptoms; over time, such coping behaviors can evolve into independent substance use disorders [<xref rid="B26-jcm-14-06045" ref-type="bibr">26</xref>].</p><p>In addition, the concept of polysubstance use highlights the inherent comorbidity and overlapping risk profiles among substance use disorders. Tobacco use, for instance, often co-occurs with alcohol dependence, with cross-sensitization and shared reinforcement pathways increasing vulnerability to multiple substances [<xref rid="B27-jcm-14-06045" ref-type="bibr">27</xref>]. Further, socioeconomic disadvantages associated with AUD, such as reduced access to care, financial stress, and poor treatment adherence, can exacerbate psychiatric symptoms and reduce resilience, indirectly encouraging broader substance use as coping. The convergence of these factors, self-medication, psychiatric comorbidity, and socioeconomic vulnerability, offers a coherent explanation for why individuals with AUD demonstrate elevated use of other substances.</p><p>Regarding sex differences within the AUD group, our data show that cocaine use was more prevalent among women (5.92% vs. 3.47%), as was cannabinoid use (4.39% vs. 2.63%) and opioid dependence (5.26% vs. 2.73%). These findings are consistent with studies indicating that women with AUD may be more likely to use certain substances compared to their male counterparts. For instance, a study by Grischott et al. [<xref rid="B28-jcm-14-06045" ref-type="bibr">28</xref>] found that women in Opioid Agonist Treatment (OAT) had a higher prevalence of substance misuse, including tobacco, alcohol, and illicit drugs, compared to men. A key explanation for these sex-specific differences lies in the higher burden of psychiatric comorbidities observed in women with AUD. Internalizing disorders like depression and anxiety are strongly associated with AUD, and individuals may resort to alcohol as a form of self-medication. This concept can be extended to explain the increased use of other substances by women with AUD, as they might be employing these additional substances to manage a broader spectrum of underlying psychological distress or psychiatric symptoms.</p><p>The data from our study indicate a significant increase in the prevalence of various comorbidities among patients with AUD hospitalized for COPD between 2016 and 2023. Notably, psychiatric disorders such as depression, anxiety, and personality disorders were more prevalent in the AUD group compared to non-AUD patients. These findings align with existing literature. So, a systematic review and meta-analysis reported that COPD patients have a significantly higher prevalence of psychiatric comorbidities, including depression and anxiety, compared to non-COPD individuals. The odds ratios for these conditions ranged from 1.78 to 1.96, indicating a substantial association [<xref rid="B29-jcm-14-06045" ref-type="bibr">29</xref>]. Moreover, a study conducted in Spain found that COPD patients exhibited higher rates of mental disorders, psychological distress, and psychiatric medication use compared to controls [<xref rid="B30-jcm-14-06045" ref-type="bibr">30</xref>]. The significant association between AUD and various substance use and psychiatric comorbidities is as well supported by prior studies. Internalizing disorders such as depression and anxiety are strongly associated with AUD. Individuals with these conditions may use alcohol as a form of self-medication, leading to a higher risk of developing AUD [<xref rid="B31-jcm-14-06045" ref-type="bibr">31</xref>]. The slight increase in the Charlson Comorbidity Index over time in our study is consistent with findings from other research indicating that the burden of comorbidities in COPD patients tends to rise with disease progression [<xref rid="B32-jcm-14-06045" ref-type="bibr">32</xref>].</p><p>Conversely, conditions like pneumonia and asthma were less common in the AUD cohort. This contrasts with some studies that have reported higher rates of respiratory infections and comorbid asthma among individuals with substance use disorders [<xref rid="B33-jcm-14-06045" ref-type="bibr">33</xref>,<xref rid="B34-jcm-14-06045" ref-type="bibr">34</xref>]. However, the specific relationship between AUD and these conditions in the context of COPD requires further investigation. Additionally, the lower incidence of COVID-19 among AUD patients in our study may reflect differences in healthcare access, comorbidity profiles, or other factors that warrant further exploration.</p><p>Between 2016 and 2023 in Spain, ICU admissions among COPD patients increased slightly, with those diagnosed with AUD exhibiting greater ICU resource use&#8212;particularly women. Despite this heightened ICU utilization, in-hospital mortality paradoxically remained lower among AUD patients across both sexes. This suggests that although AUD is linked with more intensive care needs, it does not necessarily drive higher mortality, possibly due to differences in age profiles, illness severity, or care pathways within this subgroup.</p><p>International literature examining ICU outcomes in patients with AUD mirrors our conclusions regarding intensive care utilization but often indicates higher mortality. A prospective cohort study in Scotland found that 34.4% of ICU admissions involved patients with AUD, and alcohol dependence was independently associated with significantly greater odds of ICU mortality (OR 2.28) and hospital mortality (OR 2.43) after adjustment for lifestyle factors and age [<xref rid="B35-jcm-14-06045" ref-type="bibr">35</xref>]. In U.S. populations, COPD and asthma patients with AUD had higher rates of respiratory failure (OR 1.32) and need for mechanical ventilation in emergency settings, as well as increased ICU admissions, lengthier hospital stays, and greater likelihood of 30 day readmission [<xref rid="B6-jcm-14-06045" ref-type="bibr">6</xref>]. Together, these studies indicate that AUD heightens the risk of severe critical illness and intensive care resource use; however, our finding of lower in-hospital mortality among AUD-afflicted COPD patients&#8212;especially women&#8212;suggests that patient demographics, clinical profiles, and treatment pathways may modulate outcomes.</p><p>Multivariate modeling identified several significant determinants of in hospital mortality among COPD patients with alcohol use disorder. Advanced age, especially in elderly women, constituted the most substantial mortality risk. Coexisting infections, most notably pneumonia and COVID 19, as well as a greater burden of comorbidities, significantly elevated the likelihood of in hospital death. Literature largely supports our multivariate findings: advanced age, pneumonia, COVID 19 infection, and comorbidity burden notably increase mortality risk [<xref rid="B36-jcm-14-06045" ref-type="bibr">36</xref>,<xref rid="B37-jcm-14-06045" ref-type="bibr">37</xref>,<xref rid="B38-jcm-14-06045" ref-type="bibr">38</xref>]. Conversely, some chronic conditions, including obesity, sleep apnea, and various psychiatric disorders, were associated with reduced mortality risk.</p><p>The observed protective effect of obesity aligns with the well-documented &#8220;obesity paradox&#8221; in COPD, whereby overweight and obese individuals hospitalized for exacerbations exhibit lower adjusted in-hospital and long-term mortality rates [<xref rid="B39-jcm-14-06045" ref-type="bibr">39</xref>]. This paradox has been supported by several large-scale studies, which suggest that excess body mass may confer metabolic and nutritional reserves that help buffer against the catabolic stress of acute illness, particularly in elderly patients [<xref rid="B40-jcm-14-06045" ref-type="bibr">40</xref>]. Furthermore, obese patients may receive earlier or more aggressive medical attention due to heightened clinical vigilance, potentially improving outcomes.</p><p>Similarly, the association between obstructive sleep apnea (OSA) and reduced in-hospital mortality in COPD patients may, in part, be attributed to its frequent co-occurrence with obesity and increased clinical recognition. Patients with diagnosed OSA are more likely to receive targeted interventions such as CPAP therapy, closer monitoring, and multidisciplinary care, which can mitigate acute deterioration during hospital stays.</p><p>Finally, the association of psychiatric comorbidities (e.g., depression, anxiety, personality disorders) with lower in-hospital mortality likely reflects higher levels of healthcare engagement. Patients with diagnosed psychiatric disorders often have more frequent contact with clinical services, may adhere better to follow-up and maintenance therapies, and benefit from systematic monitoring, which could translate into improved acute outcomes [<xref rid="B41-jcm-14-06045" ref-type="bibr">41</xref>,<xref rid="B42-jcm-14-06045" ref-type="bibr">42</xref>]. While direct mechanistic studies are limited, such patterns of enhanced access and continuity of care offer plausible explanations for survival advantages in this subgroup.</p><p>We observed that the probability of AUD decreases with increasing age, while male sex serves as a strong independent predictor. The observed decline in AUD prevalence with advancing age aligns with national surveillance data across populations [<xref rid="B43-jcm-14-06045" ref-type="bibr">43</xref>]. Male predominance in AUD risk, often showing roughly 3&#8211;4 times higher odds, is well documented in multivariable analyses [<xref rid="B44-jcm-14-06045" ref-type="bibr">44</xref>].</p><p>Taken together, and building on our findings, alcohol use should be regarded as a potential treatable trait in hospitalized COPD patients, reflecting its rising prevalence and impact on ICU utilization, substance comorbidity, and outcomes. This proposal aligns with GesEPOC 2021&#8217;s fourth pillar of COPD care, which advocates for the systematic identification and management of treatable traits (clinical, physiological, or biological characteristics with targeted interventions) alongside exacerbation and risk stratification pathways [<xref rid="B45-jcm-14-06045" ref-type="bibr">45</xref>]. Embedding alcohol use assessment and, when indicated, early brief interventions or referrals within COPD treatment protocols enables a more individualized, holistic care approach that integrates respiratory and addiction management, thereby optimizing both pulmonary and overall patient outcomes.</p><p>One of the key strengths of this study lies in its extensive sample size, encompassing a large and nationally representative cohort of COPD patients. This broad representation enhances the robustness of the analysis and supports the validity and generalizability of the findings across the national population. However, our study, utilizing the SNHDD, also presents several limitations inherent to administrative health data. Firstly, the reliance on ICD-10 coding for diagnosis classification may introduce inaccuracies due to coding errors, misclassification, or underreporting, especially for conditions not directly related to the primary reason for hospitalization. However, this methodology has previously been used to identify patients with both AUD [<xref rid="B46-jcm-14-06045" ref-type="bibr">46</xref>,<xref rid="B47-jcm-14-06045" ref-type="bibr">47</xref>] and COPD [<xref rid="B48-jcm-14-06045" ref-type="bibr">48</xref>,<xref rid="B49-jcm-14-06045" ref-type="bibr">49</xref>]. Additionally, the absence of clinical details such as disease severity, laboratory results, or medication adherence limits the depth of our analyses, potentially leading to residual confounding. Moreover, the observational nature of the study precludes causal inferences, and the lack of post-discharge data restricts our understanding of long-term outcomes and the dynamics between alcohol use disorder and chronic obstructive pulmonary disease. Lastly, variations in coding practices and data collection standards across different hospitals may introduce inconsistencies, impacting the overall validity and comparability of the data.</p></sec><sec sec-type="conclusions" id="sec5-jcm-14-06045"><title>5. Conclusions</title><p>Our study reveals a concerning upward trend in the prevalence of AUD among hospitalized COPD patients in Spain, particularly among women. This demographic shift underscores the need for gender-sensitive approaches in both clinical care and public health strategies. The high comorbidity between AUD and other substance use disorders, such as tobacco, cocaine, cannabis, and opioids, highlights the complex interplay between these conditions and the necessity for integrated treatment plans. Additionally, the increased prevalence of psychiatric comorbidities, including depression, anxiety, and personality disorders, among AUD patients suggests a multifaceted pathophysiology that warrants comprehensive management. Despite greater utilization of intensive care resources, the paradoxical lower in-hospital mortality rates among AUD patients may reflect differences in patient demographics and disease severity, pointing to the importance of individualized care approaches.</p><p>Therefore, we recommend implementing routine, systematic screening for AUD within COPD treatment protocols to facilitate early identification and tailored interventions, aligning with the &#8220;treatable traits&#8221; framework. Furthermore, given the disproportionate increase in AUD and psychiatric comorbidities observed specifically among women with COPD, healthcare strategies must evolve to incorporate gender-sensitive approaches, including specialized assessment tools and integrated therapeutic interventions, to improve engagement in care and optimize outcomes for this vulnerable subgroup.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-jcm-14-06045"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/jcm14176045/s1">https://www.mdpi.com/article/10.3390/jcm14176045/s1</uri>, Table S1: Diagnosis analyzed with their corresponding ICD10 codes; Table S2: Clinical characteristics and hospital outcomes in alcohol use disorders (AUD) in adults with COPD in Spain according to gender (2016&#8211;2023).</p><supplementary-material id="jcm-14-06045-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jcm-14-06045-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, T.G.-G., R.J.-G. and J.d.-M.-D.; methodology A.L.-d.-A., D.C.-A. and A.B.-P.; validation, E.L.-G. and A.J.-S.; data curation, V.H.-B.; Formal analysis, V.H.-B.; Funding: J.d.-M.-D., A.L.-d.-A. and R.J.-G.; Writing&#8212;original draft T.G.-G., R.J.-G. and J.d.-M.-D.; Writing&#8212;review and editing, A.L.-d.-A., A.B.-P., A.J.-S., D.C.-A. and E.L.-G. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The dataset provided for this study was completely anonymized and did not contain any personally identifiable information. As the data were obtained for research purposes in an anonymous and aggregate format, and in accordance with Spanish legislation governing the secondary use of health data, ethical approval from a clinical research ethics committee was not required.</p></notes><notes><title>Informed Consent Statement</title><p>The database was made available to the research team free of charge, and its use complied fully with national regulations on the protection of personal data and the ethical standards of epidemiological research. The Spanish legislation is available at: Ley 14/2007; de 3 de julio, de investigaci&#243;n biom&#233;dica. Agencia Estatal Bolet&#237;n Oficial del Estado: Madrid, Spain, 2007. Available online: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.boe.es/eli/es/l/2007/07/03/14">https://www.boe.es/eli/es/l/2007/07/03/14</uri> (accessed on 31 March 2025). Also according to this law as this is an administrative database informed consent is not necessary.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>According to the contract signed with the Spanish Ministry of Health and Social Services, which provided access to the databases from the Spanish National Hospital Database, we cannot share the databases with any other investigator, and we have to destroy the databases once the investigation has concluded. Consequently, we cannot upload the databases to any public repository. However, any investigator can apply for access to the databases by filling out the questionnaire available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.sanidad.gob.es/estadEstudios/estadisticas/estadisticas/estMinisterio/SolicitudCMBD.htm">https://www.sanidad.gob.es/estadEstudios/estadisticas/estadisticas/estMinisterio/SolicitudCMBD.htm</uri> (accessed on 16 December 2024). All other relevant data are included in the paper.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">COPD</td><td align="left" valign="middle" rowspan="1" colspan="1">Chronic Obstructive Pulmonary Disease </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MBDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Mental and Behavioral Disorders due to substance Abuse </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AUD</td><td align="left" valign="middle" rowspan="1" colspan="1">Alcohol Use Disorder</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SNHDD</td><td align="left" valign="middle" rowspan="1" colspan="1">Spanish National Hospital Discharge Database</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HIV</td><td align="left" valign="middle" rowspan="1" colspan="1">Human Immunodeficiency Virus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICU</td><td align="left" valign="middle" rowspan="1" colspan="1">Intensive Care Units </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICD-10-CM</td><td align="left" valign="middle" rowspan="1" colspan="1">International Classification of Diseases, 10th Revision, Clinical Modification</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IHM</td><td align="left" valign="middle" rowspan="1" colspan="1">In-Hospital Mortality</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OSA</td><td align="left" valign="middle" rowspan="1" colspan="1">Obstructive Sleeping Apnea</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OAT</td><td align="left" valign="middle" rowspan="1" colspan="1">Opioid Agonist Treatment</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-jcm-14-06045"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terry</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Dhand</surname><given-names>R.</given-names></name></person-group><article-title>The 2023 GOLD Report: Updated Guidelines for Inhaled Pharmacological Therapy in Patients with Stable COPD</article-title><source>Pulm. Ther.</source><year>2023</year><volume>9</volume><fpage>345</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1007/s41030-023-00233-z</pub-id><pub-id pub-id-type="pmid">37470971</pub-id><pub-id pub-id-type="pmcid">PMC10447769</pub-id></element-citation></ref><ref id="B2-jcm-14-06045"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soriano</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Alfageme</surname><given-names>I.</given-names></name><name name-style="western"><surname>Miravitlles</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Lucas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Soler-Catalu&#241;a</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Garc&#237;a-R&#237;o</surname><given-names>F.</given-names></name><name name-style="western"><surname>Casanova</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rodr&#237;guez Gonz&#225;lez-Moro</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Cos&#237;o</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Prevalence and Determinants of COPD in Spain: EPISCAN II</article-title><source>Arch. Bronconeumol. Engl. Ed.</source><year>2021</year><volume>57</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.arbres.2020.07.024</pub-id><pub-id pub-id-type="pmid">32950310</pub-id></element-citation></ref><ref id="B3-jcm-14-06045"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Putcha</surname><given-names>N.</given-names></name><name name-style="western"><surname>Drummond</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Wise</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Hansel</surname><given-names>N.N.</given-names></name></person-group><article-title>Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management</article-title><source>Semin. Respir. Crit. Care Med.</source><year>2015</year><volume>36</volume><fpage>575</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1055/s-0035-1556063</pub-id><pub-id pub-id-type="pmid">26238643</pub-id><pub-id pub-id-type="pmcid">PMC5004772</pub-id></element-citation></ref><ref id="B4-jcm-14-06045"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>May</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.T.</given-names></name></person-group><article-title>Burden of chronic obstructive pulmonary disease: Healthcare costs and beyond</article-title><source>Allergy Asthma Proc.</source><year>2015</year><volume>36</volume><fpage>4</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.2500/aap.2015.36.3812</pub-id><pub-id pub-id-type="pmid">25562549</pub-id><pub-id pub-id-type="pmcid">PMC5554331</pub-id></element-citation></ref><ref id="B5-jcm-14-06045"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Nagar</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Dalal</surname><given-names>A.A.</given-names></name></person-group><article-title>Indirect costs in chronic obstructive pulmonary disease: A review of the economic burden on employers and individuals in the United States</article-title><source>Int. J. Chron. Obs. Pulm. Dis.</source><year>2014</year><volume>9</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.2147/COPD.S57157</pub-id><pub-id pub-id-type="pmid">24672234</pub-id><pub-id pub-id-type="pmcid">PMC3964024</pub-id></element-citation></ref><ref id="B6-jcm-14-06045"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacMurdo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Udeh</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Zein</surname><given-names>J.G.</given-names></name></person-group><article-title>Alcohol use disorder and healthcare utilization in patients with chronic asthma and obstructive lung disease</article-title><source>Alcohol</source><year>2021</year><volume>93</volume><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.alcohol.2021.03.002</pub-id><pub-id pub-id-type="pmid">33713754</pub-id><pub-id pub-id-type="pmcid">PMC8315839</pub-id></element-citation></ref><ref id="B7-jcm-14-06045"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Lindenauer</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P.-C.</given-names></name><name name-style="western"><surname>Imrey</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Haessler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>A.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Rothberg</surname><given-names>M.B.</given-names></name></person-group><article-title>Association Between Alcohol Use Disorders and Outcomes of Patients Hospitalized With Community-Acquired Pneumonia</article-title><source>JAMA Netw. Open</source><year>2019</year><volume>2</volume><fpage>e195172</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.5172</pub-id><pub-id pub-id-type="pmid">31173120</pub-id><pub-id pub-id-type="pmcid">PMC6563577</pub-id></element-citation></ref><ref id="B8-jcm-14-06045"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akkuzinova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>K.</given-names></name><name name-style="western"><surname>Toleuov</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moldagaliyev</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seksenbayev</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jamedinova</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ospanova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dyussupov</surname><given-names>A.</given-names></name></person-group><article-title>Differences in the Rates of Diagnoses of Mental and Behavioral Disorders Due to Psychoactive Substance Use by Sex and Age during Pre-Pandemic and COVID-19 Pandemic Periods in Kazakhstan</article-title><source>Healthcare</source><year>2024</year><volume>12</volume><elocation-id>2012</elocation-id><pub-id pub-id-type="doi">10.3390/healthcare12202012</pub-id><pub-id pub-id-type="pmid">39451427</pub-id><pub-id pub-id-type="pmcid">PMC11506856</pub-id></element-citation></ref><ref id="B9-jcm-14-06045"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grant</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pickering</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III</article-title><source>JAMA Psychiatry</source><year>2015</year><volume>72</volume><fpage>757</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2015.0584</pub-id><pub-id pub-id-type="pmid">26039070</pub-id><pub-id pub-id-type="pmcid">PMC5240584</pub-id></element-citation></ref><ref id="B10-jcm-14-06045"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaluza</surname><given-names>J.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Linden</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wolk</surname><given-names>A.</given-names></name></person-group><article-title>Alcohol Consumption and Risk of Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study of Men</article-title><source>Am. J. Epidemiol.</source><year>2019</year><volume>188</volume><fpage>907</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1093/aje/kwz020</pub-id><pub-id pub-id-type="pmid">30877760</pub-id></element-citation></ref><ref id="B11-jcm-14-06045"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wetherbee</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Niewoehner</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Sisson</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lindberg</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Connett</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Kunisaki</surname><given-names>K.M.</given-names></name></person-group><article-title>Self-reported alcohol intake and risk of acute exacerbations of chronic obstructive pulmonary disease: A prospective cohort study</article-title><source>Int. J. Chron. Obs. Pulm. Dis.</source><year>2015</year><volume>10</volume><fpage>1363</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.2147/COPD.S86572</pub-id><pub-id pub-id-type="pmcid">PMC4516185</pub-id><pub-id pub-id-type="pmid">26229455</pub-id></element-citation></ref><ref id="B12-jcm-14-06045"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaphalia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Calhoun</surname><given-names>W.J.</given-names></name></person-group><article-title>Alcoholic lung injury: Metabolic, biochemical and immunological aspects</article-title><source>Toxicol. Lett.</source><year>2013</year><volume>222</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2013.07.016</pub-id><pub-id pub-id-type="pmid">23892124</pub-id><pub-id pub-id-type="pmcid">PMC3806189</pub-id></element-citation></ref><ref id="B13-jcm-14-06045"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasmussen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stafford</surname><given-names>D.</given-names></name><name name-style="western"><surname>LaFontaine</surname><given-names>J.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Antony</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Raju</surname><given-names>S.V.</given-names></name></person-group><article-title>Alcohol-Induced Mucociliary Dysfunction: Role of Defective CFTR Channel Function</article-title><source>BioRxiv</source><year>2023</year><pub-id pub-id-type="doi">10.1101/2023.07.17.548927</pub-id></element-citation></ref><ref id="B14-jcm-14-06045"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Traphagen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Allen-Gipson</surname><given-names>D.</given-names></name></person-group><article-title>Chronic Ethanol Exposure: Pathogenesis of Pulmonary Disease and Dysfunction</article-title><source>Biomolecules</source><year>2015</year><volume>5</volume><fpage>2840</fpage><lpage>2853</lpage><pub-id pub-id-type="doi">10.3390/biom5042840</pub-id><pub-id pub-id-type="pmid">26492278</pub-id><pub-id pub-id-type="pmcid">PMC4693259</pub-id></element-citation></ref><ref id="B15-jcm-14-06045"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Ministerio de Sanidad</collab><collab>Servicios Sociales e Igualdad</collab></person-group><article-title>Real Decreto 69/2015, de 6 de Febrero, Por el Que se Regula el Registro de Actividad de Atenci&#243;n Sanitaria Especializada. (Spanish National Hospital Discharge Database)</article-title><source>BOE</source><year>2015</year><volume>35</volume><fpage>10789</fpage><lpage>10809</lpage><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mscbs.gob.es/estadEstudios/estadisticas/docs/BOE_RD_69_2015_RAE_CMBD.pdf" ext-link-type="uri">https://www.mscbs.gob.es/estadEstudios/estadisticas/docs/BOE_RD_69_2015_RAE_CMBD.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-31">(accessed on 31 March 2025)</date-in-citation></element-citation></ref><ref id="B16-jcm-14-06045"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundararajan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>C.</given-names></name><name name-style="western"><surname>Muggivan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ghali</surname><given-names>W.A.</given-names></name></person-group><article-title>New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality</article-title><source>J. Clin. Epidemiol.</source><year>2004</year><volume>57</volume><fpage>1288</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2004.03.012</pub-id><pub-id pub-id-type="pmid">15617955</pub-id></element-citation></ref><ref id="B17-jcm-14-06045"><label>17.</label><element-citation publication-type="book"><source>Joinpoint Regression Program, Version 5.4.0.0-April 2025</source><publisher-name>Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute</publisher-name><publisher-loc>Rockville, MD, USA</publisher-loc><year>2025</year></element-citation></ref><ref id="B18-jcm-14-06045"><label>18.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Hosmer</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Lemeshow</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sturdivant</surname><given-names>R.X.</given-names></name></person-group><source>Applied Logistic Regression</source><edition>3rd ed.</edition><publisher-name>John Wiley &amp; Sons, Inc.</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2013</year></element-citation></ref><ref id="B19-jcm-14-06045"><label>19.</label><element-citation publication-type="book"><source>Ley 14/2007, de 3 de Julio, de Investigaci&#243;n Biom&#233;dica</source><publisher-name>Agencia Estatal Bolet&#237;n Oficial del Estado</publisher-name><publisher-loc>Madrid, Spain</publisher-loc><year>2007</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.boe.es/eli/es/l/2007/07/03/14" ext-link-type="uri">https://www.boe.es/eli/es/l/2007/07/03/14</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-31">(accessed on 31 March 2025)</date-in-citation></element-citation></ref><ref id="B20-jcm-14-06045"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Moreno</surname><given-names>A.</given-names></name><name name-style="western"><surname>P&#233;rez-R&#237;os</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guerra-Tort</surname><given-names>C.</given-names></name><name name-style="western"><surname>Santiago-P&#233;rez</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Teijeiro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martin-Gisbert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>G.</given-names></name><name name-style="western"><surname>Candal-Pedreira</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rey-Brandariz</surname><given-names>J.</given-names></name></person-group><article-title>Evolution of the prevalence of alcohol consumption and characterization of hazardous consumption in Spain: 2005&#8211;2022</article-title><source>Med. Clin.</source><year>2025</year><volume>164</volume><fpage>106909</fpage><pub-id pub-id-type="doi">10.1016/j.medcli.2025.106909</pub-id><pub-id pub-id-type="pmid">40187126</pub-id></element-citation></ref><ref id="B21-jcm-14-06045"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliv&#225;n-Bl&#225;zquez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lear-Claveras</surname><given-names>A.</given-names></name><name name-style="western"><surname>Samper-Pardo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Le&#243;n-Herrera</surname><given-names>S.</given-names></name><name name-style="western"><surname>Magall&#243;n-Botaya</surname><given-names>R.</given-names></name></person-group><article-title>Worsening of alcohol abuse disorder in a Spanish population during the first twelve months of the COVID-19 pandemic and associated factors: Retrospective, ecological and community study</article-title><source>BMC Psychiatry</source><year>2023</year><volume>23</volume><fpage>504</fpage><pub-id pub-id-type="doi">10.1186/s12888-023-04993-5</pub-id><pub-id pub-id-type="pmid">37438682</pub-id><pub-id pub-id-type="pmcid">PMC10339574</pub-id></element-citation></ref><ref id="B22-jcm-14-06045"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsch</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Belnap</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kady</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>L.A.</given-names></name></person-group><article-title>A narrative review on alcohol use in women: Insight into the telescoping hypothesis from a biopsychosocial perspective</article-title><source>Am. J. Drug Alcohol Abuse</source><year>2025</year><volume>51</volume><fpage>14</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1080/00952990.2024.2419540</pub-id><pub-id pub-id-type="pmid">39868972</pub-id><pub-id pub-id-type="pmcid">PMC12206452</pub-id></element-citation></ref><ref id="B23-jcm-14-06045"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gum</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>King-Kallimanis</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kohn</surname><given-names>R.</given-names></name></person-group><article-title>Prevalence of mood, anxiety, and substance-abuse disorders for older Americans in the national comorbidity survey-replication</article-title><source>Am. J. Geriatr. Psychiatry</source><year>2009</year><volume>17</volume><fpage>769</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1097/JGP.0b013e3181ad4f5a</pub-id><pub-id pub-id-type="pmid">19700949</pub-id></element-citation></ref><ref id="B24-jcm-14-06045"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuerbis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sacco</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blazer</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>A.A.</given-names></name></person-group><article-title>Substance abuse among older adults</article-title><source>Clin. Geriatr. Med.</source><year>2014</year><volume>30</volume><fpage>629</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1016/j.cger.2014.04.008</pub-id><pub-id pub-id-type="pmid">25037298</pub-id><pub-id pub-id-type="pmcid">PMC4146436</pub-id></element-citation></ref><ref id="B25-jcm-14-06045"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nolan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klimas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>E.</given-names></name></person-group><article-title>Alcohol use in opioid agonist treatment</article-title><source>Addict. Sci. Clin. Pract.</source><year>2016</year><volume>11</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/s13722-016-0065-6</pub-id><pub-id pub-id-type="pmid">27931253</pub-id><pub-id pub-id-type="pmcid">PMC5146864</pub-id></element-citation></ref><ref id="B26-jcm-14-06045"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sareen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>J.M.</given-names></name></person-group><article-title>Role of self-medication in the development of comorbid anxiety and substance use disorders: A longitudinal investigation</article-title><source>Arch. Gen. Psychiatry</source><year>2011</year><volume>68</volume><fpage>800</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2011.75</pub-id><pub-id pub-id-type="pmid">21810645</pub-id></element-citation></ref><ref id="B27-jcm-14-06045"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cougle</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Hakes</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Macatee</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Zvolensky</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Chavarria</surname><given-names>J.</given-names></name></person-group><article-title>Probability and correlates of dependence among regular users of alcohol, nicotine, cannabis, and cocaine: Concurrent and prospective analyses of the National Epidemiologic Survey on Alcohol and Related Conditions</article-title><source>J. Clin. Psychiatry</source><year>2016</year><volume>77</volume><fpage>e444</fpage><lpage>e450</lpage><pub-id pub-id-type="doi">10.4088/JCP.14m09469</pub-id><pub-id pub-id-type="pmid">27137428</pub-id></element-citation></ref><ref id="B28-jcm-14-06045"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grischott</surname><given-names>T.</given-names></name><name name-style="western"><surname>Falcato</surname><given-names>L.</given-names></name><name name-style="western"><surname>Senn</surname><given-names>O.</given-names></name><name name-style="western"><surname>Puhan</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bruggmann</surname><given-names>P.</given-names></name></person-group><article-title>Chronic obstructive pulmonary disease (COPD) among opioid-dependent patients in agonist treatment. A diagnostic study</article-title><source>Addiction</source><year>2019</year><volume>114</volume><fpage>868</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1111/add.14559</pub-id><pub-id pub-id-type="pmid">30675957</pub-id></element-citation></ref><ref id="B29-jcm-14-06045"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q.Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name></person-group><article-title>Prevalence of comorbidities in chronic obstructive pulmonary disease patients: A meta-analysis</article-title><source>Medicine</source><year>2017</year><volume>96</volume><fpage>e6836</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000006836</pub-id><pub-id pub-id-type="pmid">28489768</pub-id><pub-id pub-id-type="pmcid">PMC5428602</pub-id></element-citation></ref><ref id="B30-jcm-14-06045"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuentes-Alonso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lopez-Herranz</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#243;pez-De-Andr&#233;s</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jim&#233;nez-Garc&#237;a</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maestre-Miquel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zamorano-Le&#243;n</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Jimenez-Trujillo</surname><given-names>I.</given-names></name><name name-style="western"><surname>de Miguel-Diez</surname><given-names>J.</given-names></name></person-group><article-title>Prevalence and Determinants of Mental Health among COPD Patients in a Population-Based Sample in Spain</article-title><source>J. Clin. Med.</source><year>2021</year><volume>10</volume><elocation-id>2786</elocation-id><pub-id pub-id-type="doi">10.3390/jcm10132786</pub-id><pub-id pub-id-type="pmid">34202915</pub-id><pub-id pub-id-type="pmcid">PMC8268632</pub-id></element-citation></ref><ref id="B31-jcm-14-06045"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castillo-Carniglia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Keyes</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Hasin</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Cerd&#225;</surname><given-names>M.</given-names></name></person-group><article-title>Psychiatric comorbidities in alcohol use disorder</article-title><source>Lancet Psychiatry</source><year>2019</year><volume>6</volume><fpage>1068</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(19)30222-6</pub-id><pub-id pub-id-type="pmid">31630984</pub-id><pub-id pub-id-type="pmcid">PMC7006178</pub-id></element-citation></ref><ref id="B32-jcm-14-06045"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>N.C.D.</given-names></name><name name-style="western"><surname>Miravitlles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Camelier</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>V.D.C.</given-names></name><name name-style="western"><surname>Maciel</surname><given-names>R.R.B.T.</given-names></name><name name-style="western"><surname>Camelier</surname><given-names>F.W.R.</given-names></name></person-group><article-title>Prevalence and Impact of Comorbidities in Individuals with Chronic Obstructive Pulmonary Disease: A Systematic Review</article-title><source>Tuberc. Respir. Dis.</source><year>2022</year><volume>85</volume><fpage>205</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.4046/trd.2021.0179</pub-id><pub-id pub-id-type="pmcid">PMC9263346</pub-id><pub-id pub-id-type="pmid">35618259</pub-id></element-citation></ref><ref id="B33-jcm-14-06045"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samokhvalov</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Irving</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>J.</given-names></name></person-group><article-title>Alcohol consumption as a risk factor for pneumonia: A systematic review and meta-analysis</article-title><source>Epidemiol. Infect.</source><year>2010</year><volume>138</volume><fpage>1789</fpage><lpage>1795</lpage><pub-id pub-id-type="doi">10.1017/S0950268810000774</pub-id><pub-id pub-id-type="pmid">20380771</pub-id></element-citation></ref><ref id="B34-jcm-14-06045"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Roux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cavalcanti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marcos</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ewig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mensa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>A.</given-names></name></person-group><article-title>Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia</article-title><source>Chest</source><year>2006</year><volume>129</volume><fpage>1219</fpage><lpage>1225</lpage><pub-id pub-id-type="doi">10.1378/chest.129.5.1219</pub-id><pub-id pub-id-type="pmid">16685012</pub-id></element-citation></ref><ref id="B35-jcm-14-06045"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McPeake</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217; Neill</surname><given-names>A.</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>E.</given-names></name><name name-style="western"><surname>Puxty</surname><given-names>A.</given-names></name><name name-style="western"><surname>Quasim</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kinsella</surname><given-names>J.</given-names></name></person-group><article-title>Do alcohol use disorders impact on long term outcomes from intensive care?</article-title><source>Crit. Care</source><year>2015</year><volume>19</volume><fpage>185</fpage><pub-id pub-id-type="doi">10.1186/s13054-015-0909-6</pub-id><pub-id pub-id-type="pmid">25899245</pub-id><pub-id pub-id-type="pmcid">PMC4440292</pub-id></element-citation></ref><ref id="B36-jcm-14-06045"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andreen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Sundell</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gustavsson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Westin</surname><given-names>J.</given-names></name></person-group><article-title>Mortality of COVID-19 is associated with comorbidity in patients with chronic obstructive pulmonary disease</article-title><source>Infect. Dis.</source><year>2022</year><volume>54</volume><fpage>508</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1080/23744235.2022.2050422</pub-id><pub-id pub-id-type="pmid">35287524</pub-id></element-citation></ref><ref id="B37-jcm-14-06045"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>B.</given-names></name></person-group><article-title>Pneumonia Is Associated with Increased Mortality in Hospitalized COPD Patients: A Systematic Review and Meta-Analysis</article-title><source>Respiration</source><year>2021</year><volume>100</volume><fpage>64</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1159/000510615</pub-id><pub-id pub-id-type="pmid">33454702</pub-id></element-citation></ref><ref id="B38-jcm-14-06045"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luna</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Palma</surname><given-names>I.</given-names></name><name name-style="western"><surname>Niederman</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Membriani</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giovini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wiemken</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Peyrani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>J.</given-names></name></person-group><article-title>The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia</article-title><source>Ann. Am. Thorac. Soc.</source><year>2016</year><volume>13</volume><fpage>1519</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1513/AnnalsATS.201512-848OC</pub-id><pub-id pub-id-type="pmid">27398827</pub-id></element-citation></ref><ref id="B39-jcm-14-06045"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iyer</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Dransfield</surname><given-names>M.T.</given-names></name></person-group><article-title>The &#8220;Obesity Paradox&#8221; in Chronic Obstructive Pulmonary Disease: Can It Be Resolved?</article-title><source>Ann. Am. Thorac. Soc.</source><year>2018</year><volume>15</volume><fpage>158</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1513/AnnalsATS.201711-901ED</pub-id><pub-id pub-id-type="pmid">29388820</pub-id><pub-id pub-id-type="pmcid">PMC5822407</pub-id></element-citation></ref><ref id="B40-jcm-14-06045"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bunjhoo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>W.</given-names></name></person-group><article-title>Body mass index and mortality in chronic obstructive pulmonary disease: A meta-analysis</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e43892</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0043892</pub-id><pub-id pub-id-type="pmid">22937118</pub-id><pub-id pub-id-type="pmcid">PMC3427325</pub-id></element-citation></ref><ref id="B41-jcm-14-06045"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Gon&#231;alves-Pinho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>L.</given-names></name></person-group><article-title>The impact of comorbid psychiatric disorders on chronic obstructive pulmonary disease (COPD) hospitalizations: A nationwide retrospective study</article-title><source>Soc. Psychiatry Psychiatr. Epidemiol.</source><year>2024</year><volume>59</volume><fpage>2093</fpage><lpage>2103</lpage><pub-id pub-id-type="doi">10.1007/s00127-024-02645-x</pub-id><pub-id pub-id-type="pmid">38429541</pub-id></element-citation></ref><ref id="B42-jcm-14-06045"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Simoni-Wastila</surname><given-names>L.</given-names></name><name name-style="western"><surname>Albrecht</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Moyo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khokhar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>I.</given-names></name><name name-style="western"><surname>Langenberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Netzer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>S.W.</given-names></name></person-group><article-title>The association of antidepressant treatment with COPD maintenance medication use and adherence in a comorbid Medicare population: A longitudinal cohort study</article-title><source>Int. J. Geriatr. Psychiatry</source><year>2018</year><volume>33</volume><fpage>e212</fpage><lpage>e220</lpage><pub-id pub-id-type="doi">10.1002/gps.4772</pub-id><pub-id pub-id-type="pmid">28833488</pub-id><pub-id pub-id-type="pmcid">PMC6362976</pub-id></element-citation></ref><ref id="B43-jcm-14-06045"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Karno</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Grella</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>A.A.</given-names></name></person-group><article-title>Psychiatric correlates of alcohol and tobacco use disorders in U.S. adults aged 65 years and older: Results from the 2001&#8211;2002 National Epidemiologic Survey of Alcohol and Related Conditions</article-title><source>Am. J. Geriatr. Psychiatry</source><year>2014</year><volume>22</volume><fpage>1356</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1016/j.jagp.2013.07.005</pub-id><pub-id pub-id-type="pmid">24021218</pub-id><pub-id pub-id-type="pmcid">PMC3949218</pub-id></element-citation></ref><ref id="B44-jcm-14-06045"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenstr&#246;m</surname><given-names>T.</given-names></name><name name-style="western"><surname>Torvik</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Ystrom</surname><given-names>E.</given-names></name><name name-style="western"><surname>Czajkowski</surname><given-names>N.O.</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Aggen</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Kendler</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Reichborn-Kjennerud</surname><given-names>T.</given-names></name></person-group><article-title>Prediction of alcohol use disorder using personality disorder traits: A twin study</article-title><source>Addiction</source><year>2018</year><volume>113</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1111/add.13951</pub-id><pub-id pub-id-type="pmid">28734091</pub-id><pub-id pub-id-type="pmcid">PMC5725242</pub-id></element-citation></ref><ref id="B45-jcm-14-06045"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soler-Catalu&#241;a</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Pi&#241;era</surname><given-names>P.</given-names></name><name name-style="western"><surname>Trigueros</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Calle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Casanova</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cos&#237;o</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>L&#243;pez-Campos</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Molina</surname><given-names>J.</given-names></name><name name-style="western"><surname>Almagro</surname><given-names>P.</given-names></name><name name-style="western"><surname>G&#243;mez</surname><given-names>J.-T.</given-names></name><etal/></person-group><article-title>Spanish COPD Guidelines (GesEPOC) 2021 Update Diagnosis and Treatment of COPD Exacerbation Syndrome</article-title><source>Arch. Bronconeumol.</source><year>2022</year><volume>58</volume><fpage>159</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.arbres.2021.05.011</pub-id><pub-id pub-id-type="pmid">35971815</pub-id></element-citation></ref><ref id="B46-jcm-14-06045"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subhani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Talat</surname><given-names>U.</given-names></name><name name-style="western"><surname>Imtiaz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aithal</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Ryder</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Morling</surname><given-names>J.R.</given-names></name></person-group><article-title>Screening for Alcohol Use Disorder Among Hospitalised Patients: Learning from a Retrospective Cohort Study in Secondary Care</article-title><source>J. Clin. Med.</source><year>2024</year><volume>13</volume><elocation-id>7617</elocation-id><pub-id pub-id-type="doi">10.3390/jcm13247617</pub-id><pub-id pub-id-type="pmid">39768540</pub-id><pub-id pub-id-type="pmcid">PMC11678479</pub-id></element-citation></ref><ref id="B47-jcm-14-06045"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#225;&#382;m&#233;r</surname><given-names>L.</given-names></name><name name-style="western"><surname>&#352;&#237;ba</surname><given-names>O.</given-names></name><name name-style="western"><surname>Orl&#237;kov&#225;</surname><given-names>B.</given-names></name></person-group><article-title>Excess mortality in people hospitalised for alcohol use disorders before and during the pandemic-A registry-based retrospective cohort study</article-title><source>Drug Alcohol Rev.</source><year>2025</year><volume>44</volume><fpage>1229</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1111/dar.14045</pub-id><pub-id pub-id-type="pmid">40134124</pub-id><pub-id pub-id-type="pmcid">PMC12117291</pub-id></element-citation></ref><ref id="B48-jcm-14-06045"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Miguel-Diez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lopez-De-Andres</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jimenez-Garcia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Barrera</surname><given-names>V.</given-names></name><name name-style="western"><surname>Carabantes-Alarcon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zamorano-Leon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Oma&#241;a-Palanco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Barcala</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Cuadrado-Corrales</surname><given-names>N.</given-names></name></person-group><article-title>Trends in prevalence and the effects on hospital outcomes of dementia in patients hospitalized with acute COPD exacerbation</article-title><source>Respir. Med.</source><year>2023</year><volume>212</volume><fpage>107223</fpage><pub-id pub-id-type="doi">10.1016/j.rmed.2023.107223</pub-id><pub-id pub-id-type="pmid">36965589</pub-id></element-citation></ref><ref id="B49-jcm-14-06045"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez-Garc&#237;a</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>De-Miguel-D&#237;ez</surname><given-names>J.</given-names></name><name name-style="western"><surname>L&#243;pez-De-Andr&#233;s</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Barrera</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jimenez-Sierra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cuadrado-Corrales</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zamorano-Le&#243;n</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Carabantes-Alarc&#243;n</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bodas-Pinedo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jim&#233;nez-Garc&#237;a</surname><given-names>R.</given-names></name></person-group><article-title>Prevalence of Respiratory Syncytial Virus Infection in Hospitalized COPD Patients in Spain Between 2018&#8211;2022</article-title><source>Diseases</source><year>2025</year><volume>13</volume><elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.3390/diseases13010023</pub-id><pub-id pub-id-type="pmid">39851487</pub-id><pub-id pub-id-type="pmcid">PMC11764113</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="jcm-14-06045-f001" orientation="portrait"><label>Figure 1</label><caption><p>Joinpoint regression for the prevalence of mental and behavioral disorders due to use of alcohol (AUD) over all COPD hospital admissions in Spain (2016&#8211;2023).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-14-06045-g001.jpg"/></fig><fig position="float" id="jcm-14-06045-f002" orientation="portrait"><label>Figure 2</label><caption><p>Joinpoint regression for the prevalence of mental and behavioral disorders due to use of alcohol (AUD) in men with COPD hospital admissions in Spain (2016&#8211;2023).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-14-06045-g002.jpg"/></fig><fig position="float" id="jcm-14-06045-f003" orientation="portrait"><label>Figure 3</label><caption><p>Joinpoint regression for the prevalence of mental and behavioral disorders due to use of alcohol (AUD) in women with COPD hospital admissions in Spain (2016&#8211;2023).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-14-06045-g003.jpg"/></fig><table-wrap position="float" id="jcm-14-06045-t001" orientation="portrait"><object-id pub-id-type="pii">jcm-14-06045-t001_Table 1</object-id><label>Table 1</label><caption><p>Number, gender, age, and clinical characteristics and hospital outcomes of alcohol use disorders (AUD) in adults with COPD in Spain (2016&#8211;2023).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2016</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2017</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2018</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2019</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2020</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2021</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2022</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2023</th><th rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic toggle="yes">p</italic> for Trend</th></tr><tr><th colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th></tr></thead><tbody><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Number of COPD hospital admissions</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">303,406</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">323,500</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">334,768</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">333,415</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">282,377</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">291,073</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">331,539</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">345,073</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Number of AUD</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26,288 (8.66)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30,399 (9.4)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32,009 (9.56)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33,989 (10.19)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32,103 (11.37)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35,481 (12.19)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39,918 (12.04)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43,381 (12.57)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Gender</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24,292 (92.41)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28,018 (92.17)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29,394 (91.83)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31,068 (91.41)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29,347 (91.42)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32,154 (90.62)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35,932 (90.01)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38,631 (89.05)</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1996 (7.59)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2381 (7.83)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2615 (8.17)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2921 (8.59)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2756 (8.58)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3327 (9.38)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3986 (9.99)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4750 (10.95)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Age in years. Mean (SD)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.68 (10.7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.07 (10.64)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.88 (10.51)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.11 (10.52)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.33 (10.46)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.73 (10.34)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.94 (10.36)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69.18 (10.22)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Age groups<break/>(years)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40&#8211;49</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1224 (18.78)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1344 (20.38)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1317 (20.02)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1294 (20.42)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1139 (21.07)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1109 (21.1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1141 (20.56)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1102 (19.15)</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#8211;64</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8891 (17.73)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9880 (18.57)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,830 (18.68)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,299 (19.54)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,530 (21.13)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,375 (22.27)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,618 (22.07)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13,393 (22.19)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65&#8211;79</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,099 (9.35)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14,294 (10.47)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,064 (10.64)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16,277 (11.33)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,525 (12.69)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17,417 (13.79)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19,753 (13.49)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21,902 (14.11)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8805;80</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4074 (3.47)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4881 (3.84)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4798 (3.73)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5119 (4.07)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4909 (4.68)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5580 (5.15)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6406 (5.24)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6984 (5.64)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Cocaine use</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">655 (2.49)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">790 (2.6)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">949 (2.96)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1158 (3.41)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1235 (3.85)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1401 (3.95)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1806 (4.52)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2109 (4.86)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Cannabinoids use</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">533 (2.03)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">638 (2.1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">687 (2.15)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">889 (2.62)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1008 (3.14)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1035 (2.92)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1328 (3.33)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1507 (3.47)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Opioid dependence</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">632 (2.4)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">719 (2.37)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">885 (2.76)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1023 (3.01)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">978 (3.05)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1154 (3.25)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1273 (3.19)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1419 (3.27)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Tobacco use</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21,688 (82.5)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25,501 (83.89)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26,687 (83.37)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28,744 (84.57)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27,108 (84.44)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29,808 (84.01)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33,801 (84.68)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36,758 (84.73)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">CCI, Mean (SD)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.35 (1.1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.38 (1.12)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.41 (1.13)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.45 (1.14)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5 (1.16)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.54 (1.17)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.48 (1.16)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.48 (1.16)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Pneumonia</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2893 (11.01)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3305 (10.87)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3516 (10.98)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3716 (10.93)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3252 (10.13)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2954 (8.33)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3882 (9.72)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4981 (11.48)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Asthma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">388 (1.48)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">590 (1.94)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">824 (2.57)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">835 (2.46)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">925 (2.88)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1089 (3.07)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1235 (3.09)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1415 (3.26)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Sleep apnea</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3014 (11.47)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3612 (11.88)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4030 (12.59)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4524 (13.31)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4218 (13.14)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4989 (14.06)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5617 (14.07)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6069 (13.99)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Obesity</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3484 (13.25)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4075 (13.41)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4341 (13.56)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4773 (14.04)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4710 (14.67)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5685 (16.02)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6058 (15.18)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6583 (15.17)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Depression</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1170 (4.45)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1331 (4.38)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1367 (4.27)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1485 (4.37)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1470 (4.58)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1543 (4.35)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1790 (4.48)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1978 (4.56)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.467</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Anxiety </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">611 (2.32)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">813 (2.67)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1130 (3.53)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1260 (3.71)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1358 (4.23)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1633 (4.6)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1915 (4.8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2266 (5.22)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Personality disorders</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">357 (1.36)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">420 (1.38)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">450 (1.41)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">460 (1.35)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">594 (1.85)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">592 (1.67)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">745 (1.87)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">814 (1.88)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">External causes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1249 (4.75)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1442 (4.74)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1641 (5.13)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1786 (5.25)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1824 (5.68)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2085 (5.88)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2277 (5.7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2653 (6.12)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">COVID-19</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">910 (2.83)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1723 (4.86)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3784 (9.48)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1828 (4.21)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Long-term use of steroid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">437 (1.66)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">613 (2.02)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">901 (2.81)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1281 (3.77)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1102 (3.43)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1462 (4.12)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1772 (4.44)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2148 (4.95)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Supplemental oxygen</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2698 (10.26)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3365 (11.07)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3726 (11.64)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3903 (11.48)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3428 (10.68)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3759 (10.59)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4412 (11.05)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4742 (10.93)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Invasive ventilation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">685 (2.61)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">779 (2.56)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">815 (2.55)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">804 (2.37)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">790 (2.46)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">842 (2.37)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">943 (2.36)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1031 (2.38)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.207</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Non-Invasive ventilation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">765 (2.91)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">929 (3.06)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1357 (4.24)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1481 (4.36)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1369 (4.26)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1712 (4.83)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2001 (5.01)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2261 (5.21)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Admission to ICU </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1872 (7.12)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2102 (6.91)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2381 (7.44)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2543 (7.48)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2177 (6.78)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2426 (6.84)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2956 (7.41)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3380 (7.79)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">IHM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1798 (6.84)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2161 (7.11)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2284 (7.14)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2397 (7.05)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2722 (8.48)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2870 (8.09)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2998 (7.51)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3184 (7.34)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>COPD: chronic obstructive pulmonary disease. AUD: alcohol use disorders. CCI: Charlson comorbidity index. External causes included ICD 10 codes for accidents, Injury and Intentional self-harm (See <xref rid="app1-jcm-14-06045" ref-type="app">Table S1</xref>). ICU: intensive care unit. IHM: in-hospital mortality. NA: not available. <italic toggle="yes">p</italic> value for time trend.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-14-06045-t002" orientation="portrait"><object-id pub-id-type="pii">jcm-14-06045-t002_Table 2</object-id><label>Table 2</label><caption><p>Clinical characteristics and hospital outcomes in adults with COPD, with and without alcohol use disorders (AUD) in Spain according to gender (2016&#8211;2023).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">BOTH GENDER</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">MALE</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">FEMALE</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not AUD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not AUD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not AUD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age Mean (SD)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.44 (10.97)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.44 (10.46)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.84 (10.44)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.93 (10.39)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74.3 (12.28)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63.45 (9.91)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40&#8211;49 years, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38,321 (1.69)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9670 (3.53)</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22,857 (1.36)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7867 (3.16)</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,464 (2.62)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1803 (7.29)</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#8211;64 years, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">348,788 (15.35)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88,816 (32.47)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">225,403 (13.41)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76,749 (30.84)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">123,385 (20.88)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,067 (48.79)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65&#8211;79, <italic toggle="yes">n</italic> (%) years</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">969,269 (42.67)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132,331 (48.37)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">746,983 (44.45)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">122,988 (49.43)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">222,286 (37.61)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9343 (37.78)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8805;80, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">915,205 (40.29)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42,751 (15.63)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">685,277 (40.78)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41,232 (16.57)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">229,928 (38.9)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1519 (6.14)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cocaine use, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,130 (0.45)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,103 (3.69)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7618 (0.45)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8639 (3.47)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2512 (0.42)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1464 (5.92)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabinoids use, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7650 (0.34)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7625 (2.79)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6120 (0.36)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6539 (2.63)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1530 (0.26)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1086 (4.39)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Opioid dependence, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14,743 (0.65)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8083 (2.95)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,767 (0.64)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6781 (2.73)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3976 (0.67)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1302 (5.26)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tobacco use, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1,120,608 (49.33)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">230,095 (84.11)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">897,417 (53.4)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">209,329 (84.12)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">223,191 (37.76)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20,766 (83.96)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCI, Mean (SD)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.29 (1.13)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.46 (1.15)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.38 (1.15)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.49 (1.15)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.05 (1.03)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.07 (0.98)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumonia, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">255,109 (11.23)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28,499 (10.42)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">196,531 (11.69)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26,187 (10.52)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58,578 (9.91)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2312 (9.35)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asthma, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107,344 (4.73)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7301 (2.67)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43,047 (2.56)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5526 (2.22)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64,297 (10.88)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1775 (7.18)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sleep apnea, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">287,675 (12.66)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36,073 (13.19)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">231,971 (13.8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34,111 (13.71)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.198</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55,704 (9.42)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1962 (7.93)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Obesity, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">290,283 (12.78)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39,709 (14.52)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">191,380 (11.39)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36,235 (14.56)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98,903 (16.73)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3474 (14.05)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Depression, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94,203 (4.15)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,134 (4.44)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45,007 (2.68)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9121 (3.67)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49,196 (8.32)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3013 (12.18)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anxiety, <italic toggle="yes">n</italic> (%) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81,174 (3.57)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,986 (4.02)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36,251 (2.16)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8149 (3.27)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44,923 (7.6)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2837 (11.47)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Personality disorders, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9527 (0.42)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4432 (1.62)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4749 (0.28)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2898 (1.16)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4778 (0.81)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1534 (6.2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">External causes, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">114,980 (5.06)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14,957 (5.47)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75,326 (4.48)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13,042 (5.24)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39,654 (6.71)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1915 (7.74)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID 19, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80,402 (3.54)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8245 (3.01)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59,780 (3.56)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7594 (3.05)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20,622 (3.49)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">651 (2.63)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Long-term use of steroid, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77,218 (3.4)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9716 (3.55)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53,408 (3.18)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8681 (3.49)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23,810 (4.03)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1035 (4.18)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.220</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Supplemental oxygen, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">287,707 (12.67)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30,033 (10.98)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">209,354 (12.46)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26,982 (10.84)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78,353 (13.26)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3051 (12.34)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Invasive mechanical ventilation, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37,436 (1.65)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6689 (2.45)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27,827 (1.66)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5927 (2.38)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9609 (1.63)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">762 (3.08)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-invasive mechanical ventilation, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86,260 (3.8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,875 (4.34)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59,662 (3.55)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,372 (4.17)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26,598 (4.5)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1503 (6.08)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Admission to ICU <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">131,686 (5.8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19,837 (7.25)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100,750 (6)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17,904 (7.2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30,936 (5.23)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1933 (7.82)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IHM, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">186,241 (8.2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20,414 (7.46)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">144,731 (8.61)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18,989 (7.63)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41,510 (7.02)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1425 (5.76)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>COPD: chronic obstructive pulmonary disease. AUD: alcohol use disorders. CCI: Charlson comorbidity index. External causes included ICD 10 codes for accidents, Injury and Intentional self-harm (See <xref rid="app1-jcm-14-06045" ref-type="app">Table S1</xref>). ICU: intensive care unit. IHM: in-hospital mortality. <italic toggle="yes">p</italic> value for time trend.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-14-06045-t003" orientation="portrait"><object-id pub-id-type="pii">jcm-14-06045-t003_Table 3</object-id><label>Table 3</label><caption><p>Multivariable analysis of study variables associated with alcohol use disorders (AUD) in adults with COPD in Spain, according to gender (2016&#8211;2023).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BOTH GENDER</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MALE</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FEMALE</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study Variable</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Categories</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OR (95%CI)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OR (95%CI)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OR (95%CI)</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Age groups (years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40&#8211;49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#8211;64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.06 (1.03&#8211;1.08)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.09 (1.06&#8211;1.13)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.95 (0.89&#8211;1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65&#8211;79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58 (0.57&#8211;0.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6 (0.58&#8211;0.62)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.54 (0.51&#8211;0.58)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8805;80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24 (0.23&#8211;0.24)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25 (0.24&#8211;0.26)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15 (0.14&#8211;0.16)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Cocaine use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.6 (2.51&#8211;2.69)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.54 (2.45&#8211;2.64)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.69 (2.47&#8211;2.94)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Cannabinoids use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.32 (2.23&#8211;2.41)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.17 (2.08&#8211;2.26)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.44 (3.13&#8211;3.77)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Opioid dependence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.12 (1.09&#8211;1.16)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.07 (1.03&#8211;1.11)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.41 (1.3&#8211;1.53)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Tobacco use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.06 (4.02&#8211;4.11)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.95 (3.9&#8211;3.99)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.84 (4.66&#8211;5.02)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">CCI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.21 (1.2&#8211;1.21)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2 (1.2&#8211;1.21)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.27 (1.26&#8211;1.29)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Asthma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8 (0.78&#8211;0.82)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82 (0.8&#8211;0.85)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76 (0.72&#8211;0.8)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Sleep apnea</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.84 (0.83&#8211;0.85)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.84 (0.83&#8211;0.85)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.78 (0.75&#8211;0.82)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Obesity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.06 (1.05&#8211;1.07)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.11 (1.1&#8211;1.13)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.72 (0.69&#8211;0.75)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Depression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.34 (1.31&#8211;1.36)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.31 (1.28&#8211;1.34)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.42 (1.36&#8211;1.48)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Anxiety </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.21 (1.18&#8211;1.24)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.22 (1.19&#8211;1.25)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.19 (1.14&#8211;1.24)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Personality disorders</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.49 (2.39&#8211;2.59)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.04 (1.94&#8211;2.15)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.35 (3.14&#8211;3.58)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">External causes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.55 (1.53&#8211;1.58)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.52 (1.49&#8211;1.55)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.85 (1.76&#8211;1.95)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">COVID 19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.86 (0.83&#8211;0.88)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.86 (0.84&#8211;0.89)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.78 (0.72&#8211;0.85)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Long-term use of steroid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.02 (1&#8211;1.04)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.03 (1.01&#8211;1.06)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.94 (0.88&#8211;1)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Supplemental oxygen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.88 (0.86&#8211;0.89)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.87 (0.86&#8211;0.89)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.91 (0.87&#8211;0.95)</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Year of admission</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.06 (1.04&#8211;1.08)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.06 (1.04&#8211;1.09)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.03 (0.97&#8211;1.1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.07 (1.05&#8211;1.09)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.07 (1.05&#8211;1.09)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.01 (0.95&#8211;1.07)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.1 (1.08&#8211;1.12)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.11 (1.08&#8211;1.13)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.06 (1&#8211;1.13)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.24 (1.21&#8211;1.26)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.24 (1.22&#8211;1.27)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.17 (1.1&#8211;1.24)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.35 (1.33&#8211;1.38)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.36 (1.33&#8211;1.38)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.29 (1.22&#8211;1.37)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.35 (1.33&#8211;1.38)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.36 (1.34&#8211;1.39)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.25 (1.18&#8211;1.32)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4 (1.37&#8211;1.42)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4 (1.38&#8211;1.43)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.32 (1.25&#8211;1.4)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Gender</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.54 (3.49&#8211;3.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn><p>OR: Odds Ratio. CI: Confidence Interval. CCI: Charlson comorbidity index. NA: Not available.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-14-06045-t004" orientation="portrait"><object-id pub-id-type="pii">jcm-14-06045-t004_Table 4</object-id><label>Table 4</label><caption><p>Clinical characteristics and hospital outcomes in alcohol use disorders (AUD) in adults with COPD, in Spain, according to in hospital mortality and gender (2016&#8211;2023).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">BOTH GENDER</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">MALE</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">FEMALE</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NOT IHM</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IHM</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NOT IHM</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IHM</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NOT IHM</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IHM</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age Mean (SD)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.17 (10.44)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.74 (10.14)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.67 (10.37)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72.1 (10.06)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63.23 (9.86)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.04 (9.96)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40&#8211;49 years, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9413 (3.72)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">257 (1.26)</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7648 (3.33)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">219 (1.15)</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1765 (7.57)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38 (2.67)</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#8211;64 years, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84,027 (33.19)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4789 (23.46)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72,515 (31.55)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4234 (22.3)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,512 (49.39)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">555 (38.95)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65&#8211;79, <italic toggle="yes">n</italic> (%) years</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">121,825 (48.12)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,506 (51.46)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">113,151 (49.23)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9837 (51.8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8674 (37.22)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">669 (46.95)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8805;80, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37,889 (14.97)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4862 (23.82)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36,533 (15.89)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4699 (24.75)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1356 (5.82)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">163 (11.44)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cocaine use, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9761 (3.86)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">342 (1.68)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8324 (3.62)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">315 (1.66)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1437 (6.17)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 (1.89)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabinoids use, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7336 (2.9)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">289 (1.42)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6271 (2.73)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">268 (1.41)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1065 (4.57)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21 (1.47)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Opioid dependence, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7769 (3.07)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">314 (1.54)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6494 (2.83)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">287 (1.51)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1275 (5.47)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 (1.89)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tobacco use, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">213,821 (84.46)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16,274 (79.72)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">194,173 (84.48)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,156 (79.81)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19,648 (84.3)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1118 (78.46)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCI, Mean (SD)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.43 (1.14)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.81 (1.15)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.46 (1.15)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.84 (1.16)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.05 (0.98)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.43 (0.98)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumonia, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25,386 (10.03)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3113 (15.25)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23,289 (10.13)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2898 (15.26)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2097 (9)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">215 (15.09)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asthma, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6932 (2.74)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">369 (1.81)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5233 (2.28)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">293 (1.54)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1699 (7.29)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76 (5.33)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sleep apnea, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34,128 (13.48)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1945 (9.53)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32,255 (14.03)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1856 (9.77)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1873 (8.04)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89 (6.25)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Obesity, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37,566 (14.84)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2143 (10.5)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34,260 (14.91)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1975 (10.4)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3306 (14.18)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">168 (11.79)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Depression, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,470 (4.53)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">664 (3.25)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8589 (3.74)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">532 (2.8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2881 (12.36)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132 (9.26)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anxiety, <italic toggle="yes">n</italic> (%) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,424 (4.12)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">562 (2.75)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7702 (3.35)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">447 (2.35)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2722 (11.68)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">115 (8.07)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Personality disorders, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4273 (1.69)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">159 (0.78)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2769 (1.2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">129 (0.68)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1504 (6.45)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 (2.11)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">External causes, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13,902 (5.49)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1055 (5.17)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.050</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,075 (5.25)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">967 (5.09)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.338</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1827 (7.84)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88 (6.18)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID 19, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7180 (2.84)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1065 (5.22)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6595 (2.87)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">999 (5.26)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">585 (2.51)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66 (4.63)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Long-term use of steroid, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9076 (3.59)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">640 (3.14)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8091 (3.52)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">590 (3.11)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">985 (4.23)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 (3.51)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.189</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Supplemental oxygen, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27,342 (10.8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2691 (13.18)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24,498 (10.66)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2484 (13.08)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2844 (12.2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">207 (14.53)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Invasive mechanical ventilation, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4322 (1.71)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2367 (11.59)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3813 (1.66)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2114 (11.13)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">509 (2.18)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">253 (17.75)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-invasive mechanical ventilation, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,152 (4.01)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1723 (8.44)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8810 (3.83)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1562 (8.23)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1342 (5.76)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">161 (11.3)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Admission to ICU <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16,104 (6.36)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3733 (18.29)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14,542 (6.33)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3362 (17.7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1562 (6.7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">371 (26.04)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24,490 (9.67)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1798 (8.81)</td><td rowspan="8" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22,597 (9.83)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1695 (8.93)</td><td rowspan="8" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">&lt;0.001</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1893 (8.12)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103 (7.23)</td><td rowspan="8" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">0.118</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28,238 (11.15)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2161 (10.59)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26,007 (11.31)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2011 (10.59)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2231 (9.57)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150 (10.53)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29,725 (11.74)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2284 (11.19)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27,253 (11.86)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2141 (11.27)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2472 (10.61)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">143 (10.04)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31,592 (12.48)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2397 (11.74)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28,819 (12.54)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2249 (11.84)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2773 (11.9)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">148 (10.39)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29,381 (11.61)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2722 (13.33)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26,800 (11.66)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2547 (13.41)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2581 (11.07)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">175 (12.28)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32,611 (12.88)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2870 (14.06)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29,498 (12.83)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2656 (13.99)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3113 (13.36)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">214 (15.02)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36,920 (14.58)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2998 (14.69)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33,170 (14.43)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2762 (14.55)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3750 (16.09)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">236 (16.56)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40,197 (15.88)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3184 (15.6)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35,703 (15.53)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2928 (15.42)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4494 (19.28)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">256 (17.96)</td></tr></tbody></table><table-wrap-foot><fn><p>COPD: chronic obstructive pulmonary disease. AUD: alcohol use disorders. CCI: Charlson comorbidity index. External causes included ICD 10 codes for accidents, Injury and Intentional self-harm (See <xref rid="app1-jcm-14-06045" ref-type="app">Table S1</xref>). ICU: intensive care unit. IHM: in-hospital mortality. <italic toggle="yes">p</italic> value for time trend.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-14-06045-t005" orientation="portrait"><object-id pub-id-type="pii">jcm-14-06045-t005_Table 5</object-id><label>Table 5</label><caption><p>Multivariable analysis of study variables associated with in hospital mortality in alcohol use disorders (AUD) in adults with COPD in Spain, according to gender (2016&#8211;2023).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BOTH GENDER</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MALE</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FEMALE</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study Variable</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Categories</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OR(95%CI)</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OR(95%CI)</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OR(95%CI)</th></tr></thead><tbody><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Age groups (years)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40&#8211;49</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#8211;64</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.77 (1.55&#8211;2.02)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.75 (1.52&#8211;2.02)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.83 (1.29&#8211;2.6)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65&#8211;79</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.51 (2.2&#8211;2.86)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.47 (2.14&#8211;2.85)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.77 (1.94&#8211;3.94)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8805;80</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.87 (3.38&#8211;4.42)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8 (3.29&#8211;4.39)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.72 (3.21&#8211;6.94)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Cocaine use</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7 (0.62&#8211;0.8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71 (0.62&#8211;0.8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.66 (0.43&#8211;1.01)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Cannabinoids use</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.85 (0.75&#8211;0.97)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.87 (0.76&#8211;1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.65 (0.41&#8211;1.04)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Opioid dependence</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.79 (0.7&#8211;0.89)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82 (0.72&#8211;0.94)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.54 (0.36&#8211;0.82)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Tobacco use</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.84 (0.81&#8211;0.88)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.85 (0.81&#8211;0.88)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.84 (0.73&#8211;0.97)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Charlson Comorbidity Index</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3 (1.28&#8211;1.32)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.29 (1.28&#8211;1.31)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.39 (1.32&#8211;1.46)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Pneumonia</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.41 (1.35&#8211;1.47)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.41 (1.35&#8211;1.47)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.46 (1.24&#8211;1.73)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Asthma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.78 (0.7&#8211;0.87)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.78 (0.69&#8211;0.88)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81 (0.63&#8211;1.03)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Sleep apnea</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.67 (0.63&#8211;0.7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.66 (0.63&#8211;0.7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71 (0.56&#8211;0.91)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Obesity</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.66 (0.63&#8211;0.69)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.65 (0.62&#8211;0.68)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76 (0.64&#8211;0.91)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Depression</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81 (0.74&#8211;0.88)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82 (0.75&#8211;0.9)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.74 (0.61&#8211;0.89)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Anxiety </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81 (0.74&#8211;0.88)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.83 (0.75&#8211;0.91)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.74 (0.6&#8211;0.91)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Personality disorders</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76 (0.64&#8211;0.89)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.89 (0.74&#8211;1.06)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48 (0.33&#8211;0.7)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">External causes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.95 (0.89&#8211;1.02)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97 (0.91&#8211;1.04)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76 (0.6&#8211;0.95)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">COVID 19</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8 (1.68&#8211;1.93)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.79 (1.67&#8211;1.93)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.89 (1.43&#8211;2.5)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Long-term use of steroid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.89 (0.82&#8211;0.97)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9 (0.82&#8211;0.98)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.83 (0.61&#8211;1.12)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Supplemental oxygen</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.31 (1.25&#8211;1.37)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.31 (1.25&#8211;1.37)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3 (1.11&#8211;1.53)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Invasive mechanical ventilation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.17 (4.83&#8211;5.53)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.12 (4.77&#8211;5.5)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.34 (4.26&#8211;6.68)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Non&#8211;invasive mechanical ventilation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.89 (1.78&#8211;2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.93 (1.81&#8211;2.05)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.58 (1.3&#8211;1.91)</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">ICU</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.94 (1.84&#8211;2.05)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.9 (1.8&#8211;2.01)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5 (2.07&#8211;3)</td></tr><tr><td rowspan="8" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Year of admission</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.04 (0.97&#8211;1.11)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.03 (0.96&#8211;1.1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.15 (0.87&#8211;1.5)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.03 (0.97&#8211;1.1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.03 (0.96&#8211;1.11)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.76&#8211;1.31)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.02 (0.96&#8211;1.09)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.02 (0.96&#8211;1.1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.94 (0.71&#8211;1.23)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.23 (1.15&#8211;1.31)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.22 (1.15&#8211;1.31)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.23 (0.94&#8211;1.6)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.14 (1.07&#8211;1.22)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.14 (1.06&#8211;1.21)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.19 (0.92&#8211;1.53)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.01 (0.95&#8211;1.08)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.01 (0.95&#8211;1.08)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.77&#8211;1.28)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.01 (0.95&#8211;1.08)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.02 (0.95&#8211;1.08)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.92 (0.71&#8211;1.17)</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Gender</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.06 (1&#8211;1.12)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn><p>OR: Odds Ratio. CI: confidence interval. NA: Not Available.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>